



Clinical trial results:

A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Relationships of Different Doses of JNJ-53718678 in Children 28 Days and 3 Years of Age With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus Infection Summary

| | |
|--------------------------|----------------------------------------------|
| EudraCT number | 2016-003642-93 |
| Trial protocol | GB BE ES HU SE FR DE PL BG Outside EU/EEA IT |
| Global end of trial date | 18 April 2022 |

Results information

| | |
|--------------------------------|------------------|
| Result version number | v1 |
| This version publication date | 03 November 2022 |
| First version publication date | 03 November 2022 |

Trial information

Trial identification

| | |
|-----------------------|-----------------|
| Sponsor protocol code | 53718678RSV2002 |
|-----------------------|-----------------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT03656510 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|-------------------------------------------------------------------------------------------|
| Sponsor organisation name | Janssen Research & Development LLC |
| Sponsor organisation address | 920 Route 202, South Raritan, New Jersey, United States, 08869 |
| Public contact | Clinical Registry Group, Janssen Research & Development LLC, ClinicalTrialsEU@its.jnj.com |
| Scientific contact | Clinical Registry Group, Janssen Research & Development LLC, ClinicalTrialsEU@its.jnj.com |

Notes:

Paediatric regulatory details

| | |
|----------------------------------------------------------------------|---------------------|
| Is trial part of an agreed paediatric investigation plan (PIP) | Yes |
| EMA paediatric investigation plan number(s) | EMA-001838-PIP01-15 |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|------------------------------------------------------|--------------|
| Analysis stage | Final |
| Date of interim/final analysis | 29 June 2022 |
| Is this the analysis of the primary completion data? | No |

| | |
|----------------------------------|---------------|
| Global end of trial reached? | Yes |
| Global end of trial date | 18 April 2022 |
| Was the trial ended prematurely? | Yes |

Notes:

General information about the trial

Main objective of the trial:

The main objective of this trial was to establish antiviral activity of JNJ-53718678 as measured by respiratory syncytial virus (RSV) viral load in nasal swab samples by a quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay in children greater than or equal to (\geq) 28 days and less than or equal to (\leq) 3 years of age with RSV disease.

Protection of trial subjects:

This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements.

Background therapy: -

Evidence for comparator: -

| | |
|-----------------------------------------------------------|------------------|
| Actual start date of recruitment | 03 December 2018 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-----------------------|
| Country: Number of subjects enrolled | Argentina: 16 |
| Country: Number of subjects enrolled | Bulgaria: 24 |
| Country: Number of subjects enrolled | Brazil: 26 |
| Country: Number of subjects enrolled | Germany: 3 |
| Country: Number of subjects enrolled | Spain: 65 |
| Country: Number of subjects enrolled | United Kingdom: 2 |
| Country: Number of subjects enrolled | Hungary: 13 |
| Country: Number of subjects enrolled | Italy: 3 |
| Country: Number of subjects enrolled | Japan: 39 |
| Country: Number of subjects enrolled | Korea, Republic of: 2 |
| Country: Number of subjects enrolled | Mexico: 3 |
| Country: Number of subjects enrolled | Malaysia: 12 |
| Country: Number of subjects enrolled | Poland: 2 |
| Country: Number of subjects enrolled | Russian Federation: 2 |
| Country: Number of subjects enrolled | Sweden: 3 |
| Country: Number of subjects enrolled | Thailand: 10 |
| Country: Number of subjects enrolled | Turkey: 4 |
| Country: Number of subjects enrolled | Taiwan: 12 |
| Country: Number of subjects enrolled | United States: 4 |

| | |
|--------------------------------------|-----------------|
| Country: Number of subjects enrolled | South Africa: 1 |
| Worldwide total number of subjects | 246 |
| EEA total number of subjects | 113 |

Notes:

| Subjects enrolled per age group | |
|-------------------------------------------|-----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 215 |
| Children (2-11 years) | 31 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 0 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

A total of 246 subjects were enrolled in the study and received JNJ-53718678 or placebo. Out of 246 subjects, 242 subjects completed the study.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator |

Arms

| | |
|------------------------------|-------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Cohort 1: Placebo |

Arm description:

Subjects of age groups (age group 1: greater than or equal to [\geq] 28 days to less than [$<$] 3 months, age group 2: \geq 3 months to $<$ 6 months, and age group 3: \geq 6 months to less than or equal to [\leq] 3 years), who were hospitalized or expected to be hospitalized within 24 hours after presentation to the hospital received placebo matching to JNJ-53718678 (high volume placebo or low volume placebo to match the calculated volume of the JNJ-53718678 for the high dose or low dose, respectively) orally once daily for 7 days.

| | |
|----------------------------------------|---------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for oral suspension |
| Routes of administration | Oral use |

Dosage and administration details:

Subjects received placebo matching to JNJ-53718678 orally once daily for 7 days.

| | |
|------------------|---------------------------------|
| Arm title | Cohort 1: JNJ-53718678 Low Dose |
|------------------|---------------------------------|

Arm description:

Subjects who were hospitalized or expected to be hospitalized within 24 hours after presentation to the hospital received JNJ-53718678 1.7 milligrams per kilogram (mg/kg) for age group 1: \geq 28 days to $<$ 3 months; 2 mg/kg for age group 2: \geq 3 months to $<$ 6 months; and 3 mg/kg for age group 3: \geq 6 months to \leq 3 years, orally once daily for 7 days.

| | |
|----------------------------------------|---------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | JNJ-53718678 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for oral suspension |
| Routes of administration | Oral use |

Dosage and administration details:

Subjects received JNJ-53718678 low dose, orally once daily for 7 days.

| | |
|------------------|----------------------------------|
| Arm title | Cohort 1: JNJ-53718678 High Dose |
|------------------|----------------------------------|

Arm description:

Subjects who were hospitalized or expected to be hospitalized within 24 hours after presentation to the hospital received JNJ-53718678 5 mg/kg for age group 1: \geq 28 days to $<$ 3 months; 6 mg/kg for age group 2: \geq 3 months to $<$ 6 months; and 9 mg/kg for age group 3: \geq 6 months to \leq 3 years, orally once daily for 7 days.

| | |
|----------------------------------------|---------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | JNJ-53718678 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for oral suspension |
| Routes of administration | Oral use |

Dosage and administration details:

Subjects received JNJ-53718678 high dose, orally once daily for 7 days.

| | |
|------------------|-------------------|
| Arm title | Cohort 2: Placebo |
|------------------|-------------------|

Arm description:

As per the original dosing, outpatient of age groups (age group 1: ≥ 28 days to < 3 months, age group 2: ≥ 3 months to < 6 months, and age group 3: ≥ 6 months to ≤ 3 years) were randomised to receive placebo matching to JNJ-53718678 (high volume placebo or low volume placebo to match the calculated volume of the JNJ-53718678 for the high dose or low dose, respectively) orally once daily for 7 days. After Protocol amendment 4, subjects received placebo matching to JNJ-53718678 orally twice daily for 7 days.

| | |
|----------------------------------------|---------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for oral suspension |
| Routes of administration | Oral use |

Dosage and administration details:

Subjects received placebo matching to JNJ-53718678 orally once daily for 7 days. After Protocol amendment 4, subjects were randomised to receive placebo matching to JNJ-53718678 orally twice daily for 7 days.

| | |
|------------------|---------------------------------|
| Arm title | Cohort 2: JNJ-53718678 Low Dose |
|------------------|---------------------------------|

Arm description:

As per the original dosing, outpatients were randomised to receive JNJ-53718678 1.7 mg/kg for age group 1: ≥ 28 days to < 3 months; 2 mg/kg for age group 2: ≥ 3 months to < 6 months; and 3 mg/kg for age group 3: ≥ 6 months to ≤ 3 years, orally once daily for 7 days. After protocol amendment 4, subjects were randomised to receive JNJ-53718678 0.85 mg/kg for age group 1, JNJ-53718678 1.0 mg/kg for age group 2, and JNJ-53718678 1.5 mg/kg for age group 3, orally twice daily for 7 days.

| | |
|----------------------------------------|---------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | JNJ-53718678 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for oral suspension |
| Routes of administration | Oral use |

Dosage and administration details:

Subjects received JNJ-53718678 low dose, orally once daily for 7 days. After protocol amendment 4, subjects received JNJ-53718678 low doses, orally twice daily for 7 days.

| | |
|------------------|----------------------------------|
| Arm title | Cohort 2: JNJ-53718678 High Dose |
|------------------|----------------------------------|

Arm description:

As per the original dosing, outpatient were randomised to receive JNJ-53718678 5 mg/kg for age group 1: ≥ 28 days to < 3 months; 6 mg/kg for age group 2: ≥ 3 months to < 6 months; and 9 mg/kg for age group 3: ≥ 6 months to ≤ 3 years, orally once daily for 7 days. After protocol amendment 4, subjects were randomised to receive JNJ-53718678 2.5 mg/kg for age group 1, JNJ-53718678 3.0 mg/kg for age group 2, and JNJ-53718678 4.5 mg/kg for age group 3, orally twice daily for 7 days.

| | |
|----------------------------------------|---------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | JNJ-53718678 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for oral suspension |
| Routes of administration | Oral use |

Dosage and administration details:

Subjects received JNJ-53718678 high dose, orally once daily for 7 days. After protocol amendment 4, subjects received JNJ-53718678 high doses, orally twice daily for 7 days.

| Number of subjects in period 1 | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose |
|---------------------------------------|-------------------|---------------------------------|----------------------------------|
| | | | |
| Started | 50 | 49 | 48 |
| Completed | 48 | 48 | 48 |
| Not completed | 2 | 1 | 0 |
| Consent withdrawn by subject | 1 | 1 | - |
| Lost to follow-up | 1 | - | - |

| Number of subjects in period 1 | Cohort 2: Placebo | Cohort 2: JNJ-53718678 Low Dose | Cohort 2: JNJ-53718678 High Dose |
|---------------------------------------|-------------------|---------------------------------|----------------------------------|
| | | | |
| Started | 34 | 34 | 31 |
| Completed | 33 | 34 | 31 |
| Not completed | 1 | 0 | 0 |
| Consent withdrawn by subject | 1 | - | - |
| Lost to follow-up | - | - | - |

Baseline characteristics

Reporting groups

| | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|
| Reporting group title | Cohort 1: Placebo |
| Reporting group description: | |
| Subjects of age groups (age group 1: greater than or equal to [\geq] 28 days to less than [$<$] 3 months, age group 2: \geq 3 months to $<$ 6 months, and age group 3: \geq 6 months to less than or equal to [\leq] 3 years), who were hospitalized or expected to be hospitalized within 24 hours after presentation to the hospital received placebo matching to JNJ-53718678 (high volume placebo or low volume placebo to match the calculated volume of the JNJ-53718678 for the high dose or low dose, respectively) orally once daily for 7 days. | |
| Reporting group title | Cohort 1: JNJ-53718678 Low Dose |
| Reporting group description: | |
| Subjects who were hospitalized or expected to be hospitalized within 24 hours after presentation to the hospital received JNJ-53718678 1.7 milligrams per kilogram (mg/kg) for age group 1: \geq 28 days to $<$ 3 months; 2 mg/kg for age group 2: \geq 3 months to $<$ 6 months; and 3 mg/kg for age group 3: \geq 6 months to \leq 3 years, orally once daily for 7 days. | |
| Reporting group title | Cohort 1: JNJ-53718678 High Dose |
| Reporting group description: | |
| Subjects who were hospitalized or expected to be hospitalized within 24 hours after presentation to the hospital received JNJ-53718678 5 mg/kg for age group 1: \geq 28 days to $<$ 3 months; 6 mg/kg for age group 2: \geq 3 months to $<$ 6 months; and 9 mg/kg for age group 3: \geq 6 months to \leq 3 years, orally once daily for 7 days. | |
| Reporting group title | Cohort 2: Placebo |
| Reporting group description: | |
| As per the original dosing, outpatient of age groups (age group 1: \geq 28 days to $<$ 3 months, age group 2: \geq 3 months to $<$ 6 months, and age group 3: \geq 6 months to \leq 3 years) were randomised to receive placebo matching to JNJ-53718678 (high volume placebo or low volume placebo to match the calculated volume of the JNJ-53718678 for the high dose or low dose, respectively) orally once daily for 7 days. After Protocol amendment 4, subjects received placebo matching to JNJ-53718678 orally twice daily for 7 days. | |
| Reporting group title | Cohort 2: JNJ-53718678 Low Dose |
| Reporting group description: | |
| As per the original dosing, outpatients were randomised to receive JNJ-53718678 1.7 mg/kg for age group 1: \geq 28 days to $<$ 3 months; 2 mg/kg for age group 2: \geq 3 months to $<$ 6 months; and 3 mg/kg for age group 3: \geq 6 months to \leq 3 years, orally once daily for 7 days. After protocol amendment 4, subjects were randomised to receive JNJ-53718678 0.85 mg/kg for age group 1, JNJ-53718678 1.0 mg/kg for age group 2, and JNJ-53718678 1.5 mg/kg for age group 3, orally twice daily for 7 days. | |
| Reporting group title | Cohort 2: JNJ-53718678 High Dose |
| Reporting group description: | |
| As per the original dosing, outpatient were randomised to receive JNJ-53718678 5 mg/kg for age group 1: \geq 28 days to $<$ 3 months; 6 mg/kg for age group 2: \geq 3 months to $<$ 6 months; and 9 mg/kg for age group 3: \geq 6 months to \leq 3 years, orally once daily for 7 days. After protocol amendment 4, subjects were randomised to receive JNJ-53718678 2.5 mg/kg for age group 1, JNJ-53718678 3.0 mg/kg for age group 2, and JNJ-53718678 4.5 mg/kg for age group 3, orally twice daily for 7 days. | |

| Reporting group values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose |
|------------------------------------------|-------------------|---------------------------------|----------------------------------|
| Number of subjects | 50 | 49 | 48 |
| Age categorical | | | |
| Units: Subjects | | | |
| Infants and toddlers (28 days-23 months) | 47 | 45 | 45 |
| Children (2-11 years) | 3 | 4 | 3 |

| | | | |
|--------------------------------------------------------------------------|---------------|---------------|---------------|
| Age continuous Units: months arithmetic mean standard deviation | 8.4 ± 8.59 | 8.6 ± 8.74 | 8.5 ± 8.21 |
| Sex: Female, Male Units: Subjects | | | |
| Female | 23 | 20 | 23 |
| Male | 27 | 29 | 25 |

| Reporting group values | Cohort 2: Placebo | Cohort 2: JNJ-53718678 Low Dose | Cohort 2: JNJ-53718678 High Dose |
|--------------------------------------------------------------------------|-------------------|---------------------------------|----------------------------------|
| Number of subjects | 34 | 34 | 31 |
| Age categorical Units: Subjects | | | |
| Infants and toddlers (28 days-23 months) | 27 | 26 | 25 |
| Children (2-11 years) | 7 | 8 | 6 |
| Age continuous Units: months arithmetic mean standard deviation | 13.8 ± 10.31 | 14.8 ± 10.9 | 17.2 ± 8.81 |
| Sex: Female, Male Units: Subjects | | | |
| Female | 13 | 8 | 14 |
| Male | 21 | 26 | 17 |

| Reporting group values | Total | | |
|--------------------------------------------------------------------------|-------|--|--|
| Number of subjects | 246 | | |
| Age categorical Units: Subjects | | | |
| Infants and toddlers (28 days-23 months) | 215 | | |
| Children (2-11 years) | 31 | | |
| Age continuous Units: months arithmetic mean standard deviation | - | | |
| Sex: Female, Male Units: Subjects | | | |
| Female | 101 | | |
| Male | 145 | | |

End points

End points reporting groups

| | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|
| Reporting group title | Cohort 1: Placebo |
| Reporting group description: Subjects of age groups (age group 1: greater than or equal to [\geq] 28 days to less than [$<$] 3 months, age group 2: \geq 3 months to $<$ 6 months, and age group 3: \geq 6 months to less than or equal to [\leq] 3 years), who were hospitalized or expected to be hospitalized within 24 hours after presentation to the hospital received placebo matching to JNJ-53718678 (high volume placebo or low volume placebo to match the calculated volume of the JNJ-53718678 for the high dose or low dose, respectively) orally once daily for 7 days. | |
| Reporting group title | Cohort 1: JNJ-53718678 Low Dose |
| Reporting group description: Subjects who were hospitalized or expected to be hospitalized within 24 hours after presentation to the hospital received JNJ-53718678 1.7 milligrams per kilogram (mg/kg) for age group 1: \geq 28 days to $<$ 3 months; 2 mg/kg for age group 2: \geq 3 months to $<$ 6 months; and 3 mg/kg for age group 3: \geq 6 months to \leq 3 years, orally once daily for 7 days. | |
| Reporting group title | Cohort 1: JNJ-53718678 High Dose |
| Reporting group description: Subjects who were hospitalized or expected to be hospitalized within 24 hours after presentation to the hospital received JNJ-53718678 5 mg/kg for age group 1: \geq 28 days to $<$ 3 months; 6 mg/kg for age group 2: \geq 3 months to $<$ 6 months; and 9 mg/kg for age group 3: \geq 6 months to \leq 3 years, orally once daily for 7 days. | |
| Reporting group title | Cohort 2: Placebo |
| Reporting group description: As per the original dosing, outpatient of age groups (age group 1: \geq 28 days to $<$ 3 months, age group 2: \geq 3 months to $<$ 6 months, and age group 3: \geq 6 months to \leq 3 years) were randomised to receive placebo matching to JNJ-53718678 (high volume placebo or low volume placebo to match the calculated volume of the JNJ-53718678 for the high dose or low dose, respectively) orally once daily for 7 days. After Protocol amendment 4, subjects received placebo matching to JNJ-53718678 orally twice daily for 7 days. | |
| Reporting group title | Cohort 2: JNJ-53718678 Low Dose |
| Reporting group description: As per the original dosing, outpatients were randomised to receive JNJ-53718678 1.7 mg/kg for age group 1: \geq 28 days to $<$ 3 months; 2 mg/kg for age group 2: \geq 3 months to $<$ 6 months; and 3 mg/kg for age group 3: \geq 6 months to \leq 3 years, orally once daily for 7 days. After protocol amendment 4, subjects were randomised to receive JNJ-53718678 0.85 mg/kg for age group 1, JNJ-53718678 1.0 mg/kg for age group 2, and JNJ-53718678 1.5 mg/kg for age group 3, orally twice daily for 7 days. | |
| Reporting group title | Cohort 2: JNJ-53718678 High Dose |
| Reporting group description: As per the original dosing, outpatient were randomised to receive JNJ-53718678 5 mg/kg for age group 1: \geq 28 days to $<$ 3 months; 6 mg/kg for age group 2: \geq 3 months to $<$ 6 months; and 9 mg/kg for age group 3: \geq 6 months to \leq 3 years, orally once daily for 7 days. After protocol amendment 4, subjects were randomised to receive JNJ-53718678 2.5 mg/kg for age group 1, JNJ-53718678 3.0 mg/kg for age group 2, and JNJ-53718678 4.5 mg/kg for age group 3, orally twice daily for 7 days. | |
| Subject analysis set title | Cohorts 1 and 2: Placebo |
| Subject analysis set type | Intention-to-treat |
| Subject analysis set description: As per the original dosing, subjects of age groups (age group 1: \geq 28 days to $<$ 3 months, age group 2: \geq 3 months to $<$ 6 months, and age group 3: \geq 6 months to less than or equal to [\leq] 3 years) were randomised to receive placebo matching to JNJ-53718678 (high volume placebo or low volume placebo to match the calculated volume of the JNJ-53718678 for the high dose or low dose, respectively) orally once daily for 7 days in Cohorts 1 and 2. After protocol amendment 4, subjects in Cohort 2 were randomised to receive placebo matching to JNJ-53718678 orally twice daily for 7 days. | |
| Subject analysis set title | Cohorts 1 and 2: JNJ-53718678 Low Dose |
| Subject analysis set type | Intention-to-treat |
| Subject analysis set description: As per the original dosing, subjects were randomised to receive JNJ-53718678 1.7 mg/kg for age group 1: \geq 28 days to $<$ 3 months; 2 mg/kg for age group 2: \geq 3 months to $<$ 6 months; and 3 mg/kg for | |

age group 3: ≥ 6 months to ≤ 3 years, orally once daily for 7 days in Cohorts 1 and 2. After protocol amendment 4, subjects in Cohort 2 were randomised to receive JNJ-53718678 0.85 mg/kg for age group 1, JNJ-53718678 1.0 mg/kg for age group 2, and JNJ-53718678 1.5 mg/kg for age group 3, orally twice daily for 7 days.

| | |
|----------------------------|-----------------------------------------|
| Subject analysis set title | Cohorts 1 and 2: JNJ-53718678 High Dose |
| Subject analysis set type | Intention-to-treat |

Subject analysis set description:

As per the original dosing, subjects were randomised to receive JNJ-53718678 5 mg/kg for age group 1: ≥ 28 days to < 3 months; 6 mg/kg for age group 2: ≥ 3 months to < 6 months; and 9 mg/kg for age group 3: ≥ 6 months to ≤ 3 years, orally once daily for 7 days in Cohorts 1 and 2. After protocol amendment 4, subjects in Cohort 2 were randomised to receive JNJ-53718678 2.5 mg/kg for age group 1, JNJ-53718678 3.0 mg/kg for age group 2, and JNJ-53718678 4.5 mg/kg for age group 3, orally twice daily for 7 days.

Primary: Respiratory Syncytial Virus (RSV) Viral Load Area Under Curve from Immediately Prior to First Dose of Study Drug Through Day 5 (AUC[Day5])

| | |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Respiratory Syncytial Virus (RSV) Viral Load Area Under Curve from Immediately Prior to First Dose of Study Drug Through Day 5 (AUC[Day5]) ^[1] |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

RSV viral load AUC from immediately prior to first dose of study drug through day 5 was determined. The RSV viral load was measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay in mid-turbinate nasal swab specimens. As planned, combined data for both the cohorts was collected, analysed and reported for this endpoint. Intent-To-Treat-infected (ITT-i) analysis set included all randomised subjects who received at least one dose of study drug and who had a centrally confirmed RSV RNA viral load of greater than or equal to (\geq) 1 log₁₀ copies/mL above the lower limit of quantification (LLOQ) of the RSV RT-qPCR assay at baseline. Analyses on the ITT-i set were performed as randomised.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Baseline through Day 5

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No inferential statistics was done. Only descriptive statistics was performed.

| End point values | Cohorts 1 and 2: Placebo | Cohorts 1 and 2: JNJ-53718678 Low Dose | Cohorts 1 and 2: JNJ-53718678 High Dose | |
|---------------------------------------------------------|--------------------------|----------------------------------------|-----------------------------------------|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 79 | 80 | 72 | |
| Units: log ₁₀ copies*day per milliliter (mL) | | | | |
| arithmetic mean (confidence interval 95%) | 22.74 (21.677 to 23.800) | 21.48 (20.402 to 22.566) | 21.51 (20.374 to 22.650) | |

Statistical analyses

No statistical analyses for this end point

Secondary: RSV Viral Load Over Time

| | |
|-----------------|--------------------------|
| End point title | RSV Viral Load Over Time |
|-----------------|--------------------------|

End point description:

RSV viral load actual values over time were measured by qRT-PCR in the nasal swab specimens collected at the clinic visits and at home. As planned, combined data for both the cohorts was collected,

analysed and reported for this endpoint. ITT-i analysis set included all randomised subjects who received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of ≥ 1 log₁₀ copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised. Here, 'n' (number analysed) represents number of subjects evaluable at the specified timepoints.

| | |
|------------------------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Baseline, Days 3, 5, 8, 14, and 21 | |

| End point values | Cohorts 1 and 2: Placebo | Cohorts 1 and 2: JNJ-53718678 Low Dose | Cohorts 1 and 2: JNJ-53718678 High Dose | |
|--------------------------------------|--------------------------|----------------------------------------|-----------------------------------------|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 79 | 80 | 72 | |
| Units: log ₁₀ copies/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline (n=79, 80, 72) | 6.913 (± 1.3449) | 7.113 (± 1.3667) | 7.004 (± 1.4709) | |
| Day 3 (n=77, 79, 71) | 5.398 (± 1.5834) | 5.432 (± 1.8952) | 5.271 (± 1.7710) | |
| Day 5 (n=77, 77, 72) | 4.146 (± 1.8508) | 4.079 (± 1.8760) | 3.883 (± 1.9815) | |
| Day 8 (n=78, 73, 70) | 2.604 (± 2.0857) | 2.108 (± 1.8538) | 2.078 (± 1.8319) | |
| Day 14 (n=73, 74, 67) | 1.640 (± 1.9515) | 1.636 (± 2.2221) | 1.440 (± 1.8768) | |
| Day 21 (n=74, 78, 68) | 1.150 (± 1.7752) | 0.817 (± 1.5347) | 0.810 (± 1.6699) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in RSV Viral Load Over Time

| | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|
| End point title | Change From Baseline in RSV Viral Load Over Time |
| End point description: | |
| Change from baseline in RSV viral load over time was measured by qRT-PCR in the nasal swab specimens collected at the clinic visits and at home. As planned, combined data for both the cohorts was collected, analysed and reported for this endpoint. ITT-i analysis set included all randomised subjects who received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of ≥ 1 log ₁₀ copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised. Here, 'n' (number analysed) represents number of subjects evaluable at the specified timepoints. | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline up to Days 3, 5, 8, 14, and 21 | |

| End point values | Cohorts 1 and 2: Placebo | Cohorts 1 and 2: JNJ-53718678 Low Dose | Cohorts 1 and 2: JNJ-53718678 High Dose | |
|--------------------------------------|--------------------------|----------------------------------------|-----------------------------------------|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 79 | 80 | 72 | |
| Units: log10 copies/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 3 (n=77, 79, 71) | -1.502 (± 1.3290) | -1.690 (± 1.6225) | 1.694 (± 1.5134) | |
| Day 5 (n=77, 77, 72) | -2.754 (± 1.7699) | -3.049 (± 1.6493) | -3.121 (± 1.8453) | |
| Day 8 (n=78, 73, 70) | -4.308 (± 2.2435) | -5.017 (± 1.8563) | -4.948 (± 1.8428) | |
| Day 14 (n=73, 74, 67) | -5.292 (± 2.2968) | -5.471 (± 2.4289) | -5.578 (± 2.2707) | |
| Day 21 (n=74, 78, 68) | -5.801 (± 2.1652) | -6.302 (± 2.0439) | -6.268 (± 1.9394) | |

Statistical analyses

No statistical analyses for this end point

Secondary: RSV Viral Load AUC from Immediately Prior to First Dose of Study Drug (Baseline) Through Days 3, 8, and 14

| | |
|-----------------|------------------------------------------------------------------------------------------------------------|
| End point title | RSV Viral Load AUC from Immediately Prior to First Dose of Study Drug (Baseline) Through Days 3, 8, and 14 |
|-----------------|------------------------------------------------------------------------------------------------------------|

End point description:

RSV viral load AUC from immediately prior to first dose of study drug (baseline) through Days 3, 8, and 14 was determined. Here, '99999' indicates that no subjects analyzed for this outcome measure at Day 14 due to the study termination. As planned, combined data for both the cohorts was analysed and reported for this endpoint. ITT-i analysis set included all randomized subjects who received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of ≥ 1 log10 copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised. Here, 'n' (number analysed) represents number of subjects evaluable at the specified timepoints.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline through Days 3, 8, and 14

| End point values | Cohorts 1 and 2: Placebo | Cohorts 1 and 2: JNJ-53718678 Low Dose | Cohorts 1 and 2: JNJ-53718678 High Dose | |
|----------------------------------------------|--------------------------|----------------------------------------|-----------------------------------------|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 79 | 80 | 72 | |
| Units: log10 copies*day/mL | | | | |
| least squares mean (confidence interval 95%) | | | | |
| Day 3 (n=79, 80, 72) | 5.48 (5.129 to 5.834) | 5.36 (5.009 to 5.717) | 5.32 (4.949 to 5.695) | |
| Day 8 (n=79, 80, 72) | 2.66 (2.307 to 3.011) | 2.08 (1.716 to 2.444) | 2.08 (1.701 to 2.450) | |

| | | | | |
|--------------------|------------------------|------------------------|------------------------|--|
| Day 14 (n=0, 0, 0) | 99999 (99999 to 99999) | 99999 (99999 to 99999) | 99999 (99999 to 99999) | |
|--------------------|------------------------|------------------------|------------------------|--|

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Undetectable RSV Viral Load

| | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|
| End point title | Time to Undetectable RSV Viral Load |
| End point description: | |
| Time to undetectable RSV viral load was defined as the time in hours from first dose of study drug to first post-baseline timepoint at which the virus is undetectable and after which no more detectable virus assessments. As planned, combined data for both the cohorts was analysed and reported for this endpoint. ITT-i analysis set included all randomised subjects who received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of ≥ 1 log ₁₀ copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised. | |
| End point type | Secondary |
| End point timeframe: | |
| Up to Day 21 | |

| End point values | Cohorts 1 and 2: Placebo | Cohorts 1 and 2: JNJ-53718678 Low Dose | Cohorts 1 and 2: JNJ-53718678 High Dose | |
|----------------------------------|--------------------------|----------------------------------------|-----------------------------------------|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 79 | 80 | 72 | |
| Units: Hours | | | | |
| median (confidence interval 95%) | 467.0 (332.90 to 478.40) | 428.3 (309.50 to 480.40) | 330.7 (308.28 to 476.00) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects with Undetectable RSV Viral Load at Each Timepoint Throughout the Study

| | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| End point title | Percentage of Subjects with Undetectable RSV Viral Load at Each Timepoint Throughout the Study |
| End point description: | |
| Percentage of subjects with undetectable RSV viral load at each timepoint throughout the study were reported. As planned, combined data for both the cohorts was analysed and reported for this endpoint. ITT-i analysis set included all randomised subjects who received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of ≥ 1 log ₁₀ copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised. Here, 'n' (number analyzed) represents number of subjects evaluable at the specified timepoints. | |
| End point type | Secondary |

End point timeframe:

Baseline, Days 3, 5, 8, 14 and 21

| End point values | Cohorts 1 and 2: Placebo | Cohorts 1 and 2: JNJ-53718678 Low Dose | Cohorts 1 and 2: JNJ-53718678 High Dose | |
|-------------------------------|--------------------------|----------------------------------------|-----------------------------------------|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 79 | 80 | 72 | |
| Units: percentage of subjects | | | | |
| number (not applicable) | | | | |
| Baseline (n=79, 80, 72) | 0 | 0 | 0 | |
| Day 3 (n=77, 79, 71) | 1.3 | 3.8 | 2.8 | |
| Day 5 (n=77, 77, 72) | 7.8 | 9.1 | 11.1 | |
| Day 8 (n=78, 73, 70) | 33.3 | 38.4 | 38.6 | |
| Day 14 (n=73, 74, 67) | 54.8 | 58.1 | 58.2 | |
| Day 21 (n=74, 78, 68) | 67.6 | 76.9 | 77.9 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Parent(s)/Caregiver(s) Pediatric RSV Electronic Severity and Outcomes Rating System (PRESORS) Scores

| | |
|-----------------|------------------------------------------------------------------------------------------------------------------------------|
| End point title | Change from Baseline in Parent(s)/Caregiver(s) Pediatric RSV Electronic Severity and Outcomes Rating System (PRESORS) Scores |
|-----------------|------------------------------------------------------------------------------------------------------------------------------|

End point description:

PRESORS is a questionnaire recording presence and severity of signs and symptoms of RSV disease (fever, cough, sputum, wheezing, difficulty breathing, nasal congestion, and feeding issues). PRESORS overall RSV symptoms summary parameter consisted of 12-items, each item score ranges from 0 to 3. A summary score was derived (mean of the item scores) which also ranges from 0 to 3. The higher the score, the worse the symptom. ITT-i analysis set included all randomised subjects who received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of ≥ 1 log₁₀ copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised. Here, 'n' (number analysed) represents number of subjects evaluable at the specified timepoints.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline up to Days 3, 5, 8, 14 and 21

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | Cohort 2: Placebo |
|--------------------------------------|-------------------|---------------------------------|----------------------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 47 | 47 | 44 | 32 |
| Units: Units on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |

| | | | | |
|-----------------------------------|-----------------|-----------------|-----------------|-----------------|
| Day 3 (n=45, 40, 41, 25, 27, 26) | -0.51 (± 0.571) | -0.55 (± 0.618) | -0.70 (± 0.594) | -0.25 (± 0.576) |
| Day 5 (n=45, 41, 41, 28, 27, 26) | -0.91 (± 0.585) | -0.88 (± 0.542) | -1.11 (± 0.581) | -0.48 (± 0.576) |
| Day 8 (n=44, 41, 41, 28, 27, 26) | -1.15 (± 0.581) | -1.25 (± 0.537) | -1.39 (± 0.514) | -0.85 (± 0.526) |
| Day 14 (n=44, 39, 40, 28, 27, 26) | -1.40 (± 0.591) | -1.39 (± 0.582) | -1.59 (± 0.458) | -1.06 (± 0.529) |
| Day 21 (n=42, 40, 41, 28, 26, 26) | -1.41 (± 0.637) | -1.33 (± 0.559) | -1.56 (± 0.468) | -1.12 (± 0.529) |

| End point values | Cohort 2: JNJ-53718678 Low Dose | Cohort 2: JNJ-53718678 High Dose | | |
|--------------------------------------|---------------------------------|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 33 | 28 | | |
| Units: Units on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 3 (n=45, 40, 41, 25, 27, 26) | -0.15 (± 0.427) | -0.21 (± 0.537) | | |
| Day 5 (n=45, 41, 41, 28, 27, 26) | -0.52 (± 0.558) | -0.58 (± 0.644) | | |
| Day 8 (n=44, 41, 41, 28, 27, 26) | -0.83 (± 0.582) | -1.04 (± 0.628) | | |
| Day 14 (n=44, 39, 40, 28, 27, 26) | -1.08 (± 0.568) | -1.24 (± 0.681) | | |
| Day 21 (n=42, 40, 41, 28, 26, 26) | -1.15 (± 0.496) | -1.29 (± 0.596) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Clinician PRESORS Score

| | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|
| End point title | Change from Baseline in Clinician PRESORS Score |
| End point description: | |
| Change from baseline in clinician (for concepts: activity level, sleep disturbance, breathing problems, retractions, tachypnea, feeding problem, cough, nasal secretions, wheezing, dehydration) PRESORS scores was reported. PRESORS is a questionnaire recording presence and severity of signs and symptoms of RSV disease and consisted of 10-items, each item score ranges from 0 to 3. Overall RSV symptoms summary parameter was derived (mean of the item scores) which also ranges from 0 to 3. The higher the score, the worse the symptom. ITT-i analysis set included all randomised subjects who received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of ≥ 1 log ₁₀ copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised. Here, 'n' (number analysed) represents number of subjects evaluable at the specified timepoints. | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline up to Days 3, 5, 8, 14 and 21 | |

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | Cohort 2: Placebo |
|--------------------------------------|-------------------|---------------------------------|----------------------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 47 | 47 | 44 | 32 |
| Units: Units on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 3 (n=43, 41, 42, 29, 29, 26) | -0.45 (± 0.441) | -0.45 (± 0.517) | -0.48 (± 0.469) | -0.25 (± 0.424) |
| Day 5 (n=42, 38, 41, 28, 28, 25) | -0.73 (± 0.582) | -0.71 (± 0.424) | -0.83 (± 0.483) | -0.38 (± 0.415) |
| Day 8 (n=41, 38, 38, 30, 29, 26) | -0.92 (± 0.461) | -1.04 (± 0.396) | -1.04 (± 0.449) | -0.71 (± 0.529) |
| Day 14 (n=40, 37, 34, 28, 27, 23) | -1.10 (± 0.466) | -1.11 (± 0.428) | -1.14 (± 0.369) | -0.81 (± 0.497) |
| Day 21 (n=45, 40, 33, 29, 28, 27) | -1.13 (± 0.424) | -1.12 (± 0.433) | -1.17 (± 0.336) | -0.87 (± 0.455) |

| End point values | Cohort 2: JNJ-53718678 Low Dose | Cohort 2: JNJ-53718678 High Dose | | |
|--------------------------------------|---------------------------------|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 33 | 28 | | |
| Units: Units on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 3 (n=43, 41, 42, 29, 29, 26) | -0.21 (± 0.378) | -0.29 (± 0.338) | | |
| Day 5 (n=42, 38, 41, 28, 28, 25) | -0.37 (± 0.462) | -0.60 (± 0.516) | | |
| Day 8 (n=41, 38, 38, 30, 29, 26) | -0.63 (± 0.423) | -0.85 (± 0.552) | | |
| Day 14 (n=40, 37, 34, 28, 27, 23) | -0.77 (± 0.436) | -0.91 (± 0.541) | | |
| Day 21 (n=45, 40, 33, 29, 28, 27) | -0.81 (± 0.411) | -0.93 (± 0.524) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Resolution of RSV Symptoms

| | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|
| End point title | Time to Resolution of RSV Symptoms |
| End point description: | |
| Time to resolution from first dose of study drug until the first time of resolution of all RSV symptoms (breathing problems, retractions, tachypnea, breathing sounds, cough, tachycardia, nasal secretions, sleep disturbance, crying, illness behavior, feeding problems, and dehydration) were reported. Resolution occurs when all symptoms from the caregiver reported outcomes (ObsRO) are scored as none or mild (score of 0 or 1, respectively) for at least 24 hours. ITT-i analysis set included all randomised subjects who received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of ≥ 1 log ₁₀ copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised. | |
| End point type | Secondary |

End point timeframe:

Up to Day 21

| End point values | Cohort 1: Placebo | Cohort 1: JNJ- 53718678 Low Dose | Cohort 1: JNJ- 53718678 High Dose | Cohort 2: Placebo |
|----------------------------------|-----------------------------|----------------------------------------|-----------------------------------------|-----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 47 | 47 | 44 | 32 |
| Units: Hours | | | | |
| median (confidence interval 95%) | 193.5 (161.80 to 243.80) | 163.6 (108.70 to 198.70) | 151.8 (114.70 to 223.70) | 166.6 (141.50 to 207.20) |

| End point values | Cohort 2: JNJ- 53718678 Low Dose | Cohort 2: JNJ- 53718678 High Dose | | |
|----------------------------------|----------------------------------------|-----------------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 33 | 28 | | |
| Units: Hours | | | | |
| median (confidence interval 95%) | 206.1 (159.20 to 232.80) | 176.9 (148.30 to 264.20) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Improvement on Overall Health

| | |
|-----------------|------------------------------------------------------|
| End point title | Time to Improvement on Overall Health ^[2] |
|-----------------|------------------------------------------------------|

End point description:

Time to improvement based on general questions on overall health was reported. Time from first dose of study drug until first time status of improvement of RSV symptoms reported as "very much improved" or "much improved" based on response to question 'Would you say the child's RSV symptoms have improved, are about the same or are worse than when the child entered the study'. This endpoint was not analysed for Cohort 2 due to premature study termination. ITT-i analysis set included all randomised subjects who received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of ≥ 1 log₁₀ copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised. Here, 'N' (number of subjects analysed) signifies number of subjects who were evaluable for this endpoint.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to Day 21

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint was planned to be analyzed for specified arms only.

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | |
|----------------------------------|--------------------------|---------------------------------|----------------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 45 | 44 | 43 | |
| Units: Hours | | | | |
| median (confidence interval 95%) | 189.6 (187.80 to 192.50) | 190.2 (188.70 to 200.00) | 189.1 (186.90 to 191.90) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects by Status of RSV Symptoms Based on PRESORS Caregiver (ObsRO) General Question Over Time

| | |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Subjects by Status of RSV Symptoms Based on PRESORS Caregiver (ObsRO) General Question Over Time ^[3] |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------|

End point description:

Percentage of subjects by status of RSV symptoms based on PRESORS caregiver (ObsRO) general question over time were reported. PRESORS is a questionnaire recording presence and severity of signs and symptoms of RSV disease (fever, cough, sputum, wheezing, difficulty breathing, nasal congestion, and feeding issues). Status of RSV symptoms was assessed by a question (how would you rate the child's RSV symptoms now?) of PRESORS questionnaire that range: 1) none, 2) very mild, 3) mild, 4) moderate, 5) severe, and 6) very severe. This endpoint was not analysed for Cohort 2 due to premature study termination. ITT-i analysis set included all randomised subjects who received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of ≥ 1 log₁₀ copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised. Here, 'n' (number analysed) represents number of subjects evaluable at the specified timepoints.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Days 3, 5, 8, 14, and 21

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint was planned to be analyzed for specified arms only.

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | |
|------------------------------------|-------------------|---------------------------------|----------------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 47 | 47 | 44 | |
| Units: percentage of subjects | | | | |
| number (not applicable) | | | | |
| Baseline: None (n=45,43,41) | 0 | 0 | 0 | |
| Baseline: Very mild (n=45,43,41) | 0 | 0 | 2.4 | |
| Baseline: Mild (n=45,43,41) | 6.7 | 7.0 | 4.9 | |
| Baseline: Moderate (n=45,43,41) | 51.1 | 55.8 | 51.2 | |
| Baseline: Severe (n=45,43,41) | 37.8 | 27.9 | 41.5 | |
| Baseline: Very severe (n=45,43,41) | 4.4 | 9.3 | 0 | |
| Day 3: None (n=47,43,44) | 0 | 2.3 | 0 | |
| Day 3: Very mild (n=47,43,44) | 6.4 | 9.3 | 6.8 | |
| Day 3: Mild (n=47,43,44) | 23.4 | 18.6 | 36.4 | |
| Day 3: Moderate (n=47,43,44) | 46.8 | 48.8 | 43.2 | |
| Day 3: Severe (n=47,43,44) | 17.0 | 18.6 | 9.1 | |

| | | | | |
|-----------------------------------|------|------|------|--|
| Day 3: Very severe (n=47,43,44) | 6.4 | 2.3 | 4.5 | |
| Day 5: None (n=47,43,43) | 2.1 | 0 | 7.0 | |
| Day 5: Very mild (n=47,43,43) | 23.4 | 23.3 | 16.3 | |
| Day 5: Mild (n=47,43,43) | 38.3 | 27.9 | 32.6 | |
| Day 5: Moderate (n=47,43,43) | 21.3 | 39.5 | 41.9 | |
| Day 5: Severe (n=47,43,43) | 10.6 | 9.3 | 2.3 | |
| Day 5: Very severe (n=47,43,43) | 4.3 | 0 | 0 | |
| Day 8: None (n=46,43,42) | 13.0 | 16.3 | 26.2 | |
| Day 8: Very mild (n=46,43,42) | 30.4 | 37.2 | 28.6 | |
| Day 8: Mild (n=46,43,42) | 34.8 | 23.3 | 28.6 | |
| Day 8: Moderate (n=46,43,42) | 17.4 | 23.3 | 16.7 | |
| Day 8: Severe (n=46,43,42) | 2.2 | 0 | 0 | |
| Day 8: Very severe (n=46,43,42) | 2.2 | 0 | 0 | |
| Day 14: None (n=41,40,41) | 48.8 | 55.0 | 58.5 | |
| Day 14: Very mild (n=41,40,41) | 36.6 | 30.0 | 26.8 | |
| Day 14: Mild (n=41,40,41) | 12.2 | 2.5 | 7.3 | |
| Day 14: Moderate (n=41,40,41) | 2.4 | 10.0 | 7.3 | |
| Day 14: Severe (n=41,40,41) | 0 | 2.5 | 0 | |
| Day 14: Very severe (n=41,40,41) | 0 | 0 | 0 | |
| Day 21: None (n=27,37, 33) | 66.7 | 67.6 | 57.6 | |
| Day 21: Very mild (n=27,37, 33) | 18.5 | 18.9 | 24.2 | |
| Day 21: Mild (n=27,37, 33) | 11.1 | 2.7 | 12.1 | |
| Day 21: Moderate (n=27,37, 33) | 3.7 | 8.1 | 6.1 | |
| Day 21: Severe (n=27,37, 33) | 0 | 2.7 | 0 | |
| Day 21: Very severe (n=27,37, 33) | 0 | 0 | 0 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects by Health Status Assessment Based on PRESORS Caregiver (ObsRO) General Question Over Time

| | |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Subjects by Health Status Assessment Based on PRESORS Caregiver (ObsRO) General Question Over Time ^[4] |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------|

End point description:

Percentage of subjects by health status assessment based on PRESORS caregiver (ObsRO) general question over time were reported. PRESORS is a questionnaire recording presence and severity of signs and symptoms of RSV disease (fever, cough, sputum, wheezing, difficulty breathing, nasal congestion, and feeding issues). Health status was assessed by a question (how is the child's health now) of PRESORS score that was categorized as : 1) excellent, 2) very good, 3) good, 4) fair, 5) poor, and 6) very poor. This endpoint was not analysed for Cohort 2 due to premature study termination. ITT-i analysis set included all randomised subjects who received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of ≥ 1 log10 copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised. Here, 'n' (number analysed) represents number of subjects evaluable at the specified timepoints.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Days 3, 5, 8, 14, and 21

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint was planned to be analyzed for specified arms only.

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | |
|-------------------------------------|-------------------|---------------------------------|----------------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 47 | 47 | 44 | |
| Units: Percentage of subjects | | | | |
| number (not applicable) | | | | |
| Baseline: Excellent (n= 45, 44, 41) | 0 | 2.3 | 0 | |
| Baseline: Very good (n= 45, 44, 41) | 0 | 4.7 | 0 | |
| Baseline: Good (n= 45, 44, 41) | 4.4 | 7.0 | 7.3 | |
| Baseline: Fair (n= 45, 44, 41) | 42.2 | 51.2 | 43.9 | |
| Baseline: poor (n= 45, 44, 41) | 48.9 | 30.2 | 48.8 | |
| Baseline: Very poor (n= 45, 44, 41) | 4.4 | 4.7 | 0 | |
| Day 3: Excellent (n= 47, 44, 43) | 0 | 0 | 0 | |
| Day 3: Very good (n= 47, 44, 43) | 8.5 | 9.3 | 2.3 | |
| Day 3: Good (n= 47, 44, 43) | 23.4 | 20.9 | 34.1 | |
| Day 3: Fair (n= 47, 44, 43) | 38.3 | 46.5 | 45.5 | |
| Day 3: Poor (n= 47, 44, 43) | 21.3 | 23.3 | 13.6 | |
| Day 3: Very poor (n= 47, 44, 43) | 8.5 | 0 | 4.5 | |
| Day 5: Excellent (n= 47, 43, 43) | 2.1 | 0 | 0 | |
| Day 5: Very good (n= 47, 43, 43) | 19.1 | 9.3 | 20.9 | |
| Day 5: Good (n= 47, 43, 43) | 23.4 | 41.9 | 37.2 | |
| Day 5: Fair (n= 47, 43, 43) | 36.2 | 39.5 | 34.9 | |
| Day 5: Poor (n= 47, 43, 43) | 12.8 | 9.3 | 7.0 | |
| Day 5: Very poor (n= 47, 43, 43) | 6.4 | 0 | 0 | |
| Day 8: Excellent (n= 46, 43, 42) | 13.0 | 9.3 | 16.7 | |
| Day 8: Very Good (n= 46, 43, 42) | 23.9 | 32.6 | 21.4 | |
| Day 8: Good (n= 46, 43, 42) | 32.6 | 32.6 | 38.1 | |
| Day 8: Fair (n= 46, 43, 42) | 23.9 | 25.6 | 21.4 | |
| Day 8: Poor (n= 46, 43, 42) | 4.3 | 0 | 2.4 | |
| Day 8: Very poor (n= 46, 43, 42) | 2.2 | 0 | 0 | |
| Day 14: Excellent (n= 41, 40, 41) | 24.4 | 42.5 | 43.9 | |
| Day 14: Very good (n= 41, 40, 41) | 43.9 | 47.5 | 36.6 | |
| Day 14: Good (n= 41, 40, 41) | 19.5 | 5.0 | 9.8 | |
| Day 14: fair (n= 41, 40, 41) | 9.8 | 5.0 | 7.3 | |
| Day 14: Poor (n= 41, 40, 41) | 2.4 | 0 | 2.4 | |
| Day 14: Very poor (n= 41, 40, 41) | 0 | 0 | 0 | |
| Day 21: Excellent (n= 27,37, 33) | 55.6 | 45.9 | 45.5 | |
| Day 21: Very Good (n= 27,37, 33) | 22.2 | 32.4 | 33.3 | |
| Day 21: Good (n= 27,37, 33) | 11.1 | 13.5 | 15.2 | |
| Day 21: Fair (n= 27,37, 33) | 11.1 | 5.4 | 6.1 | |
| Day 21: Poor (n= 27,37, 33) | 0 | 2.7 | 0 | |
| Day 21: Very poor (n= 27,37, 33) | 0 | 0 | 0 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects with Worsening or Improvement Status of RSV Disease

| | |
|-----------------|-------------------------------------------------------------------------------------------|
| End point title | Percentage of Subjects with Worsening or Improvement Status of RSV Disease ^[5] |
|-----------------|-------------------------------------------------------------------------------------------|

End point description:

Percentage of subjects with worsening or improvement of RSV disease based on general questions on overall health was reported. Improvement was defined improvement of RSV symptoms reported as "very much improved, much improved, a little improved, about the same, a little worse, much worse, and very much worse" based on response to question 'Would you say the child's RSV symptoms have improved, are about the same or are worse than when the child entered the study'. This endpoint was not analysed for Cohort 2 due to premature study termination. ITT-i analysis set included all randomised subjects who received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of ≥ 1 log10 copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised. Here, 'n' (number analysed) represents number of subjects evaluable at the specified timepoints.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 14 and 21

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint was planned to be analyzed for specified arms only.

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | |
|-------------------------------------------|-------------------|---------------------------------|----------------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 47 | 47 | 44 | |
| Units: Percentage of subjects | | | | |
| number (not applicable) | | | | |
| Day 14: Very much improved (n=41, 40, 40) | 58.5 | 57.5 | 67.5 | |
| Day 14: Much improved (n=41, 40, 40) | 34.1 | 40.0 | 30.0 | |
| Day 14: A little improved (n=41, 40, 40) | 7.3 | 2.5 | 2.5 | |
| Day 14: About the same (n=41, 40, 40) | 0 | 0 | 0 | |
| Day 14: A little worse (n=41, 40, 40) | 0 | 0 | 0 | |
| Day 14: Much worse (n=41, 40, 40) | 0 | 0 | 0 | |
| Day 14: Very much worse (n=41, 40, 40) | 0 | 0 | 0 | |
| Day 21: Very much improved (n=27, 36, 32) | 77.8 | 63.9 | 56.3 | |
| Day 21: Much improved (n=27, 36, 32) | 14.8 | 30.6 | 37.5 | |
| Day 21: A little improved (n=27, 36, 32) | 3.7 | 2.8 | 3.1 | |
| Day 21: About the same (n=27, 36, 32) | 3.7 | 2.8 | 3.1 | |
| Day 21: A little worse (n=27, 36, 32) | 0 | 0 | 0 | |
| Day 21: Much worse (n=27, 36, 32) | 0 | 0 | 0 | |
| Day 21: Very much worse (n=27, 36, 32) | 0 | 0 | 0 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects by Return to Pre-RSV Disease Health Status Assessment Based on PRESORS Caregiver (ObsRO) General Question Over Time

| | |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Subjects by Return to Pre-RSV Disease Health Status Assessment Based on PRESORS Caregiver (ObsRO) General Question Over Time ^[6] |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Percentage of subjects by return to pre-RSV disease health status assessment based on PRESORS caregiver (ObsRO) general question over time was assessed by a question (Has the child's health returned to normal [how it was before RSV?]) of PRESORS score that was categorized as: 1) No, and 2) Yes. PRESORS is a questionnaire recording presence and severity of signs and symptoms of RSV disease. This endpoint was not analysed for Cohort 2 due to premature study termination. ITT-i analysis set included all randomised subjects who received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of $\geq 1 \log_{10}$ copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised. Here, 'n' (number analysed) represent number of subjects evaluable at specified timepoints.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Days 3, 5, 8, 14, and 21

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint was planned to be analyzed for specified arms only.

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | |
|-------------------------------|-------------------|---------------------------------|----------------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 47 | 47 | 44 | |
| Units: percentage of subjects | | | | |
| number (not applicable) | | | | |
| Baseline (n=11, 4,9) | 0 | 0 | 0 | |
| Day 3 (n=39, 35, 32) | 15.4 | 8.6 | 28.1 | |
| Day 5 (n=42, 37, 39) | 23.8 | 16.2 | 25.6 | |
| Day 8 (n= 40, 38, 34) | 37.5 | 44.7 | 58.8 | |
| Day 14 (n=29, 36, 32) | 72.4 | 77.8 | 84.4 | |
| Day 21 (n=27, 36, 32) | 81.5 | 86.1 | 84.4 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Respiratory Rate Over Time

| | |
|-----------------|----------------------------|
| End point title | Respiratory Rate Over Time |
|-----------------|----------------------------|

End point description:

Respiratory rate was measured by the investigator over time. The Safety analysis set included all subjects who received at least 1 dose of study agent, and were analyzed as treated, regardless of the randomised treatment group assigned. Here, 'n' (number analyzed) represents number of subjects evaluable for the specified timepoints.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Days 3, 5, 8, 14 and 21

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | Cohort 2: Placebo |
|--------------------------------------|-------------------|---------------------------------|----------------------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 50 | 49 | 48 | 34 |
| Units: Breaths/minute | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline (n=50, 49, 48, 34, 34, 31) | 45.0 (± 10.60) | 45.6 (± 11.82) | 45.7 (± 10.85) | 41.3 (± 13.66) |
| Day 3 (n=48, 48, 48, 33, 34, 31) | 44.1 (± 11.44) | 41.8 (± 10.13) | 42.7 (± 10.04) | 37.9 (± 10.16) |
| Day 5 (n=47, 45, 46, 33, 34, 31) | 38.3 (± 9.36) | 38.1 (± 9.57) | 39.1 (± 8.81) | 38.2 (± 13.37) |
| Day 8 (n=47, 44, 46, 32, 34, 31) | 35.5 (± 7.90) | 34.4 (± 7.87) | 39.2 (± 9.45) | 37.4 (± 11.70) |
| Day 14 (n=47, 45, 46, 30, 32, 29) | 35.6 (± 7.13) | 34.9 (± 8.89) | 35.2 (± 7.45) | 35.7 (± 9.27) |
| Day 21 (n=46, 48, 44, 31, 34, 31) | 36.07 (± 10.21) | 34.9 (± 8.96) | 36.6 (± 7.43) | 36.4 (± 9.61) |

| End point values | Cohort 2: JNJ-53718678 Low Dose | Cohort 2: JNJ-53718678 High Dose | | |
|--------------------------------------|---------------------------------|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 34 | 31 | | |
| Units: Breaths/minute | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline (n=50, 49, 48, 34, 34, 31) | 41.3 (± 11.76) | 37.0 (± 8.77) | | |
| Day 3 (n=48, 48, 48, 33, 34, 31) | 37.3 (± 9.54) | 34.4 (± 9.19) | | |
| Day 5 (n=47, 45, 46, 33, 34, 31) | 38.1 (± 8.89) | 35.4 (± 9.53) | | |
| Day 8 (n=47, 44, 46, 32, 34, 31) | 36.9 (± 9.75) | 34.0 (± 10.54) | | |
| Day 14 (n=47, 45, 46, 30, 32, 29) | 35.6 (± 10.53) | 32.6 (± 8.38) | | |
| Day 21 (n=46, 48, 44, 31, 34, 31) | 35.5 (± 9.65) | 34.7 (± 11.09) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Respiratory Rate

| | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|
| End point title | Change from Baseline in Respiratory Rate |
| End point description: | |
| Change from baseline in respiratory rate was derived based on the reported measurements of respiratory rate over time. The respiratory rate over time was reported by the investigator. The Safety analysis set included all subjects who received at least 1 dose of study agent, and were analyzed as treated, regardless of the randomised treatment group assigned. Here, 'n' (number analyzed) represents number of subjects evaluable for the specified timepoints. | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline to Days 3, 5, 8, 14 and 21 | |

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | Cohort 2: Placebo |
|--------------------------------------|-------------------|---------------------------------|----------------------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 50 | 49 | 48 | 34 |
| Units: Breaths/minute | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 3 (n=48, 48, 48, 33, 34, 31) | -0.8 (± 10.88) | -3.5 (± 11.99) | -3.0 (± 12.43) | -3.7 (± 12.47) |
| Day 5 (n=47, 45, 46, 33, 34, 31) | -6.5 (± 9.41) | -7.1 (± 11.13) | -7.0 (± 11.94) | -3.4 (± 8.59) |
| Day 8 (n=47,44, 46, 32, 34, 31) | -9.4 (± 9.19) | -11.4 (± 12.96) | -6.3 (± 12.69) | -4.4 (± 11.56) |
| Day 14 (n=47, 45, 46, 30, 32, 29) | -9.3 (± 9.96) | -10.3 (± 12.59) | -10.2 (± 10.92) | -6.4 (± 3.13) |
| Day 21 (n=46, 48, 44, 31, 34, 31) | -8.4 (± 10.84) | -10.4 (± 13.01) | -9.8 (± 12.36) | -5.5 (± 14.15) |

| End point values | Cohort 2: JNJ-53718678 Low Dose | Cohort 2: JNJ-53718678 High Dose | | |
|--------------------------------------|---------------------------------|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 34 | 31 | | |
| Units: Breaths/minute | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 3 (n=48, 48, 48, 33, 34, 31) | -4.0 (± 9.54) | -2.6 (± 9.20) | | |
| Day 5 (n=47, 45, 46, 33, 34, 31) | -3.3 (± 8.40) | -1.5 (± 9.62) | | |
| Day 8 (n=47,44, 46, 32, 34, 31) | -4.4 (± 10.39) | -2.9 (± 10.54) | | |
| Day 14 (n=47, 45, 46, 30, 32, 29) | -5.8 (± 12.82) | -4.0 (± 9.92) | | |
| Day 21 (n=46, 48, 44, 31, 34, 31) | -5.8 (± 11.95) | -2.3 (± 13.25) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Heart Rate Over Time

| | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| End point title | Heart Rate Over Time |
| End point description: | |
| Heart rate was measured by the investigator over time. The Safety analysis set included all subjects who received at least 1 dose of study agent, and were analyzed as treated, regardless of the randomised treatment group assigned. Here, 'n' (number analyzed) represents number of subjects evaluable for the specified timepoints. | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline, Days 3, 5, 8, 14 and 21 | |

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | Cohort 2: Placebo |
|--------------------------------------|-------------------|---------------------------------|----------------------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 50 | 49 | 48 | 34 |
| Units: Beats/minute | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline (n=50,49,48,34, 34, 31) | 143.2 (± 17.40) | 138.9 (± 17.57) | 139.0 (± 18.57) | 131.2 (± 24.28) |
| Day 3 (n=48, 48, 38, 33, 34, 31) | 138.8 (± 16.82) | 137.5 (± 18.25) | 138.5 (± 17.06) | 127.8 (± 20.99) |
| Day 5 (n=47, 46, 47, 33, 34, 31) | 136.0 (± 15.81) | 132.7 (± 18.28) | 16.1 (± 19.68) | 119.2 (± 14.75) |
| Day 8 (n=48, 44, 46, 32, 34, 31) | 133.3 (± 17.59) | 127.9 (± 18.13) | 134.0 (± 19.14) | 118.7 (± 20.25) |
| Day 14 (n=47, 45, 46, 30, 32, 29) | 131.7 (± 19.81) | 132.4 (± 19.33) | 134.4 (± 20.70) | 117.4 (± 18.17) |
| Day 21 (n=46, 48, 44, 31, 34, 31) | 128.2 (± 20.27) | 131.5 (± 15.74) | 132.5 (± 19.14) | 117.2 (± 22.56) |

| End point values | Cohort 2: JNJ-53718678 Low Dose | Cohort 2: JNJ-53718678 High Dose | | |
|--------------------------------------|---------------------------------|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 34 | 31 | | |
| Units: Beats/minute | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline (n=50,49,48,34, 34, 31) | 135.6 (± 19.35) | 126.1 (± 22.55) | | |
| Day 3 (n=48, 48, 38, 33, 34, 31) | 128.3 (± 17.97) | 118.8 (± 28.10) | | |
| Day 5 (n=47, 46, 47, 33, 34, 31) | 122.6 (± 19.85) | 120.4 (± 23.31) | | |
| Day 8 (n=48, 44, 46, 32, 34, 31) | 120.0 (± 19.61) | 118.9 (± 27.04) | | |
| Day 14 (n=47, 45, 46, 30, 32, 29) | 118.0 (± 19.17) | 115.2 (± 18.82) | | |
| Day 21 (n=46, 48, 44, 31, 34, 31) | 125.3 (± 20.95) | 115.2 (± 19.78) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Heart Rate

| | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|
| End point title | Change from Baseline in Heart Rate |
| End point description: | |
| Change from baseline in heart rate was reported. The Safety analysis set included all subjects who received at least 1 dose of study agent, and were analyzed as treated, regardless of the randomised treatment group assigned. Here, 'n' (number analyzed) represents number of subjects evaluable for the specified timepoints. | |
| End point type | Secondary |

End point timeframe:

Baseline to Days 3, 5, 8, 14 and 21

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | Cohort 2: Placebo |
|--------------------------------------|-------------------|---------------------------------|----------------------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 50 | 49 | 48 | 34 |
| Units: Beats/minute | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 3 (n=48, 48, 48, 33, 34, 31) | -4.9 (± 19.36) | -1.6 (± 19.82) | -0.6 (± 18.84) | -3.0 (± 24.71) |
| Day 5 (n=47, 46, 47, 33, 34, 31) | -7.9 (± 20.31) | -5.8 (± 22.94) | -2.9 (± 20.56) | -11.6 (± 18.55) |
| Day 8 (n=48,44, 46, 32, 34, 31) | -10.4 (± 18.45) | -12.2 (± 23.20) | -5.2 (± 22.02) | -12.7 (± 26.09) |
| Day 14 (n=47, 45, 46, 30, 32, 29) | -12.0 (± 21.79) | -6.5 (± 23.99) | -5.1 (± 22.44) | -14.4 (± 24.62) |
| Day 21 (n=46, 48, 44, 31, 34, 31) | -15.0 (± 23.80) | -7.7 (± 25.88) | -6.5 (± 19.52) | -14.0 (± 25.38) |

| End point values | Cohort 2: JNJ-53718678 Low Dose | Cohort 2: JNJ-53718678 High Dose | | |
|--------------------------------------|---------------------------------|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 34 | 31 | | |
| Units: Beats/minute | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 3 (n=48, 48, 48, 33, 34, 31) | -7.4 (± 16.83) | -7.3 (± 28.39) | | |
| Day 5 (n=47, 46, 47, 33, 34, 31) | -13.0 (± 17.11) | -5.6 (± 28.53) | | |
| Day 8 (n=48,44, 46, 32, 34, 31) | -15.6 (± 20.67) | -7.2 (± 35.90) | | |
| Day 14 (n=47, 45, 46, 30, 32, 29) | -17.7 (± 17.69) | -10.1 (± 28.02) | | |
| Day 21 (n=46, 48, 44, 31, 34, 31) | -10.4 (± 21.02) | -10.9 (± 28.63) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Body Temperature Over Time

| | |
|-----------------|----------------------------|
| End point title | Body Temperature Over Time |
|-----------------|----------------------------|

End point description:

Body temperature was reported over time (either investigator or caregiver measured). The Safety analysis set included all subjects who received at least 1 dose of study agent, and were analysed as treated, regardless of the randomized treatment group assigned. Here, 'n' (number analysed) represents number of subjects evaluable for the specified timepoints.

| | |
|-----------------------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Baseline, Days 3, 5, 8, 14 and 21 | |

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | Cohort 2: Placebo |
|--------------------------------------|-------------------|---------------------------------|----------------------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 50 | 49 | 48 | 34 |
| Units: Degree celsius | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline (n=50, 49, 48, 34, 34, 31) | 36.84 (± 0.635) | 36.64 (± 0.468) | 36.82 (± 0.623) | 36.84 (± 0.613) |
| Day 3 (n=48, 48, 48, 34, 34, 31) | 36.77 (± 0.464) | 36.87 (± 0.524) | 36.80 (± 0.601) | 37.14 (± 0.725) |
| Day 5 (n=49, 48, 48, 33, 34, 31) | 36.75 (± 0.407) | 36.54 (± 0.557) | 36.70 (± 0.408) | 36.87 (± 0.567) |
| Day 8 (n=48, 47, 48, 33, 34, 31) | 36.70 (± 0.416) | 36.73 (± 0.513) | 36.65 (± 0.441) | 36.67 (± 0.369) |
| Day 14 (n=47, 45, 47, 33, 34, 31) | 36.86 (± 0.315) | 36.68 (± 0.440) | 36.60 (± 0.396) | 36.63 (± 0.357) |
| Day 21 (n=47, 48, 47, 33, 34, 31) | 36.76 (± 0.577) | 36.67 (± 0.407) | 36.66 (± 0.573) | 36.74 (± 0.615) |

| End point values | Cohort 2: JNJ-53718678 Low Dose | Cohort 2: JNJ-53718678 High Dose | | |
|--------------------------------------|---------------------------------|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 34 | 31 | | |
| Units: Degree celsius | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline (n=50, 49, 48, 34, 34, 31) | 36.94 (± 0.845) | 36.79 (± 0.785) | | |
| Day 3 (n=48, 48, 48, 34, 34, 31) | 37.20 (± 0.694) | 36.98 (± 0.817) | | |
| Day 5 (n=49, 48, 48, 33, 34, 31) | 36.71 (± 0.348) | 36.84 (± 0.718) | | |
| Day 8 (n=48, 47, 48, 33, 34, 31) | 36.76 (± 0.536) | 36.74 (± 0.559) | | |
| Day 14 (n=47, 45, 47, 33, 34, 31) | 36.72 (± 0.364) | 36.59 (± 0.377) | | |
| Day 21 (n=47, 48, 47, 33, 34, 31) | 36.64 (± 0.292) | 36.62 (± 0.418) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Body Temperature

| | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|
| End point title | Change from Baseline in Body Temperature |
| End point description: | |
| Change from baseline in body temperature (either investigator or caregiver measured) was assessed. The Safety analysis set included all subjects who received at least 1 dose of study agent, and were analysed as treated, regardless of the randomised treatment group assigned. Here, 'n' (number analysed) represents number of subjects evaluable for the specified timepoints. | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline to Days 3, 5, 8, 14 and 21 | |

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | Cohort 2: Placebo |
|--------------------------------------|-------------------|---------------------------------|----------------------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 50 | 49 | 48 | 34 |
| Units: Degree celsius | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 3 (n=48, 48, 48, 33, 34, 30) | -0.08 (± 0.697) | 0.23 (± 0.541) | -0.02 (± 0.629) | 0.33 (± 0.768) |
| Day 5 (n=49, 48, 48, 33, 34, 30) | -0.10 (± 0.713) | -0.09 (± 0.532) | -0.12 (± 0.627) | 0.07 (± 0.700) |
| Day 8 (n=48, 47, 48, 33, 34, 30) | -0.13 (± 0.659) | 0.10 (± 0.600) | -0.17 (± 0.596) | -0.13 (± 0.588) |
| Day 14 (n=47, 45, 47, 33, 34, 30) | 0.01 (± 0.594) | 0.04 (± 0.528) | -0.21 (± 0.609) | -0.17 (± 0.687) |
| Day 21 (n=47, 48, 47, 33, 34, 30) | -0.09 (± 0.758) | 0.03 (± 0.519) | -0.17 (± 0.724) | -0.06 (± 0.704) |

| End point values | Cohort 2: JNJ-53718678 Low Dose | Cohort 2: JNJ-53718678 High Dose | | |
|--------------------------------------|---------------------------------|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 34 | 31 | | |
| Units: Degree celsius | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 3 (n=48, 48, 48, 33, 34, 30) | 0.26 (± 0.835) | 0.21 (± 0.724) | | |
| Day 5 (n=49, 48, 48, 33, 34, 30) | -0.22 (± 0.767) | -0.04 (± 0.627) | | |
| Day 8 (n=48, 47, 48, 33, 34, 30) | -0.17 (± 1.016) | -0.11 (± 0.772) | | |
| Day 14 (n=47, 45, 47, 33, 34, 30) | -0.21 (± 0.866) | -0.19 (± 0.843) | | |
| Day 21 (n=47, 48, 47, 33, 34, 30) | -0.30 (± 0.826) | -0.18 (± 0.913) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Peripheral Capillary Oxygen Saturation (SpO2) Over Time

| | |
|-----------------|---------------------------------------------------------|
| End point title | Peripheral Capillary Oxygen Saturation (SpO2) Over Time |
|-----------------|---------------------------------------------------------|

End point description:

Peripheral capillary oxygen saturation was measured by the investigator over time. The Safety analysis set included all subjects who received at least 1 dose of study agent, and were analysed as treated, regardless of the randomised treatment group assigned. Here, 'n' (number analysed) represents number of subjects evaluable at the specified timepoints.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Days 3, 5, 8, 14 and 21

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | Cohort 2: Placebo |
|--------------------------------------|-------------------|---------------------------------|----------------------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 50 | 49 | 48 | 34 |
| Units: Percentage of SpO2 | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline (n=50, 49, 48, 32, 32, 30) | 97.3 (± 2.47) | 96.5 (± 3.44) | 96.6 (± 2.10) | 96.8 (± 2.07) |
| Day 3 (n=47,48, 48, 31, 32, 29) | 96.8 (± 2.46) | 96.3 (± 2.72) | 96.0 (± 2.43) | 96.9 (± 1.77) |
| Day 5 (n=47,46, 47, 32, 32, 30) | 97.3 (± 1.67) | 96.8 (± 3.74) | 96.7 (± 2.25) | 96.9 (± 1.68) |
| Day 8 (n=46, 44, 46, 30, 32, 30) | 97.3 (± 1.99) | 97.3 (± 2.47) | 97.5 (± 1.74) | 97.8 (± 1.48) |
| Day 14 (n=44, 43, 45, 29, 29, 28) | 98.1 (± 1.42) | 98.3 (± 1.84) | 98.1 (± 1.64) | 98.6 (± 2.03) |
| Day 21 (n=45, 47, 43, 30, 32, 30) | 98.4 (± 1.47) | 98.2 (± 1.80) | 98.0 (± 2.12) | 98.5 (± 1.74) |

| End point values | Cohort 2: JNJ-53718678 Low Dose | Cohort 2: JNJ-53718678 High Dose | | |
|--------------------------------------|---------------------------------|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 34 | 31 | | |
| Units: Percentage of SpO2 | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline (n=50, 49, 48, 32, 32, 30) | 96.7 (± 1.91) | 95.9 (± 2.92) | | |
| Day 3 (n=47,48, 48, 31, 32, 29) | 96.3 (± 3.12) | 96.5 (± 2.96) | | |
| Day 5 (n=47,46, 47, 32, 32, 30) | 97.1 (± 2.12) | 97.1 (± 2.43) | | |
| Day 8 (n=46, 44, 46, 30, 32, 30) | 97.4 (± 2.69) | 97.9 (± 1.83) | | |
| Day 14 (n=44, 43, 45, 29, 29, 28) | 98.6 (± 1.53) | 98.4 (± 1.73) | | |
| Day 21 (n=45, 47, 43, 30, 32, 30) | 98.7 (± 1.36) | 98.9 (± 1.25) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Peripheral Capillary Oxygen Saturation (SpO2)

| | |
|-----------------|-----------------------------------------------------------------------|
| End point title | Change from Baseline in Peripheral Capillary Oxygen Saturation (SpO2) |
|-----------------|-----------------------------------------------------------------------|

End point description:

Change from baseline in peripheral capillary oxygen saturation levels was derived based on reported values over time. The Safety analysis set included all subjects who received at least 1 dose of study agent, and were analysed as treated, regardless of the randomised treatment group assigned. Here, 'n' (number analysed) represents number of subjects evaluable at the specified timepoints.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline to Days 3, 5, 8, 14, and 21

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | Cohort 2: Placebo |
|--------------------------------------|-------------------|---------------------------------|----------------------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 50 | 49 | 48 | 34 |
| Units: Percentage of SpO2 | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 3 (n=47, 48, 48, 31, 32, 29) | -0.5 (± 2.93) | -0.2 (± 3.09) | -0.6 (± 2.72) | 0.2 (± 2.31) |
| Day 5 (n=47, 46, 47, 31, 32, 30) | 0.0 (± 2.92) | 0.4 (± 2.93) | 0.1 (± 2.38) | 0.1 (± 2.49) |
| Day 8 (n=46, 44, 46, 30, 32, 30) | 0.1 (± 3.02) | 0.9 (± 3.53) | 0.8 (± 2.47) | 0.9 (± 2.59) |
| Day 14 (n=44, 43, 45, 29, 29, 28) | 1.0 (± 2.28) | 1.7 (± 3.08) | 1.4 (± 2.32) | 2.0 (± 2.72) |
| Day 21 (n=45, 47, 43, 29, 32, 30) | 1.1 (± 2.45) | 1.7 (± 3.38) | 1.3 (± 2.40) | 1.8 (± 2.57) |

| End point values | Cohort 2: JNJ-53718678 Low Dose | Cohort 2: JNJ-53718678 High Dose | | |
|--------------------------------------|---------------------------------|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 34 | 31 | | |
| Units: Percentage of SpO2 | | | | |
| arithmetic mean (standard deviation) | | | | |
| Day 3 (n=47, 48, 48, 31, 32, 29) | -0.4 (± 2.45) | 0.7 (± 1.63) | | |
| Day 5 (n=47, 46, 47, 31, 32, 30) | 0.4 (± 2.41) | 1.2 (± 2.54) | | |
| Day 8 (n=46, 44, 46, 30, 32, 30) | 0.8 (± 2.86) | 2.0 (± 3.36) | | |
| Day 14 (n=44, 43, 45, 29, 29, 28) | 1.8 (± 2.05) | 2.6 (± 3.06) | | |
| Day 21 (n=45, 47, 43, 29, 32, 30) | 2.0 (± 2.12) | 3.0 (± 2.80) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects who Require (re)Hospitalization During Treatment and Follow-up

| | |
|-----------------|---------------------------------------------------------------------------------------|
| End point title | Percentage of Subjects who Require (re)Hospitalization During Treatment and Follow-up |
|-----------------|---------------------------------------------------------------------------------------|

End point description:

Percentage of subjects who require (re)hospitalization during treatment and follow-up was assessed. Percentage of subjects requiring re-hospitalization following the initial hospital discharge was assessed in Cohort 1 subjects (hospitalized cohort) whilst percentage of subjects requiring hospitalization after

first dose of study drug was assessed in Cohort 2 subjects (outpatient cohort). ITT-i analysis set included all randomised subjects who received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of ≥ 1 log₁₀ copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised.

| | |
|----------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Up to Day 28 | |

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | Cohort 2: Placebo |
|-------------------------------|-------------------|---------------------------------|----------------------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 47 | 47 | 44 | 32 |
| Units: percentage of subjects | | | | |
| number (not applicable) | 6.4 | 4.3 | 2.3 | 6.3 |

| End point values | Cohort 2: JNJ-53718678 Low Dose | Cohort 2: JNJ-53718678 High Dose | | |
|-------------------------------|---------------------------------|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 33 | 28 | | |
| Units: percentage of subjects | | | | |
| number (not applicable) | 6.1 | 14.3 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Time to Return to Age-adjusted Normal Values for Vital Signs

| | |
|-----------------|---------------------------------------------------------------------------------------|
| End point title | Cohort 1: Time to Return to Age-adjusted Normal Values for Vital Signs ^[7] |
|-----------------|---------------------------------------------------------------------------------------|

End point description:

Time to return to age-adjusted normal values from first dose of study drug based on the reported vital signs (respiratory rate, heart rate, SpO₂ $\geq 92\%$, and SpO₂ $\geq 95\%$) values were assessed. ITT-i analysis set included all randomised subjects who received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of ≥ 1 log₁₀ copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised.

| | |
|----------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Up to Day 28 | |

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint was planned to be analyzed for specified arms only.

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | |
|---------------------------------------|-----------------------|---------------------------------|----------------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 47 | 47 | 44 | |
| Units: Hours | | | | |
| median (confidence interval 95%) | | | | |
| Respiratory Rate (n=47, 47, 44) | 13.6 (0.001 to 70.10) | 20.0 (0.001 to 43.50) | 30.2 (0.001 to 84.50) | |
| Heart Rate (n=47, 47, 44) | 37.3 (0.001 to 51.50) | 17.0 (0.001 to 67.50) | 10.2 (0.001 to 160.50) | |
| SpO2 >=92% on Room Air (n=47, 47, 44) | 65.4 (30.30 to 95.10) | 86.6 (45.30 to 119.20) | 68.9 (42.40 to 105.50) | |
| SpO2 >=95% on Room Air (n=47, 47, 44) | 71.3 (47.70 to 99.30) | 87.0 (47.80 to 120.00) | 92.5 (48.50 to 141.10) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Time to Discharge From Hospital

| | |
|-----------------|----------------------------------------------------------|
| End point title | Cohort 1: Time to Discharge From Hospital ^[8] |
|-----------------|----------------------------------------------------------|

End point description:

Time to discharge from hospital was derived from the reported discharge date/time and from first dose date/time. ITT-i analysis set included all randomised subjects who received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of ≥ 1 log₁₀ copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to Day 28

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint was planned to be analyzed for specified arms only.

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | |
|----------------------------------|------------------------|---------------------------------|----------------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 47 | 47 | 44 | |
| Units: Hours | | | | |
| median (confidence interval 95%) | 96.2 (88.80 to 118.00) | 95.3 (67.20 to 140.30) | 96.2 (72.10 to 144.90) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Percentage of Subjects who Required Admission to the Intensive Care Unit (ICU)

| | |
|-----------------|------------------------------------------------------------|
| End point title | Cohort 1: Percentage of Subjects who Required Admission to |
|-----------------|------------------------------------------------------------|

End point description:

Percentage of subjects who required admission to the ICU were reported. This endpoint is applicable for those subjects that were not in ICU before first dose of study drug. ITT-i analysis set included all randomised subjects who received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of ≥ 1 log₁₀ copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised. Here, 'N' (number of subjects analysed) signifies number of subjects who were evaluable for this endpoint.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to Day 21

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint was planned to be analyzed for specified arms only.

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | |
|-------------------------------|-------------------|---------------------------------|----------------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 42 | 44 | 39 | |
| Units: Percentage of subjects | | | | |
| number (not applicable) | 2.4 | 4.5 | 2.6 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Duration of ICU Stay

| | |
|-----------------|------------------------------------------------|
| End point title | Cohort 1: Duration of ICU Stay ^[10] |
|-----------------|------------------------------------------------|

End point description:

Duration of ICU stay was derived based on the reported admission/discharge date/times for ICU. Duration defined as total number of hours a subject was in ICU from first dose of study drug until study termination. ITT-i analysis set included all randomised subjects who were admitted to ICU and received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of ≥ 1 log₁₀ copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to Day 21

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was planned to be analyzed for specified arms only.

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | |
|--------------------------------------|------------------------|---------------------------------|----------------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 6 | 5 | 6 | |
| Units: Hours | | | | |
| arithmetic mean (standard deviation) | 238.22 (\pm 70.570) | 206.94 (\pm 204.940) | 127.72 (\pm 89.389) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Time to Clinical Stability Evaluated by the Investigator

| | |
|-----------------|------------------------------------------------------------------------------------|
| End point title | Cohort 1: Time to Clinical Stability Evaluated by the Investigator ^[11] |
|-----------------|------------------------------------------------------------------------------------|

End point description:

Time to clinical stability was derived based on the vitals signs assessments and supplementation end dates as collected. Time to clinical stability is defined as time from initiation of study treatment until time at which following criteria are met: Time to return to age-adjusted normal value for otherwise healthy and pre-RSV infection status for subjects with risk factor for severe RSV disease, no more oxygen supplementation or otherwise healthy subjects and with risk factor for severe RSV disease and no more IV/nasogastric tube feeding/hydration in otherwise healthy subjects or return to pre-RSV status of IV/nasogastric tube feeding/hydration in subjects with risk factor for severe RSV disease for Cohort 1 only. ITT-i analysis set included all randomised subjects who received at least one dose of study drug and had centrally confirmed RSV RNA viral load of ≥ 1 log₁₀ copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to Day 21

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was planned to be analyzed for specified arms only.

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | |
|------------------------------------------|------------------------|---------------------------------|----------------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 47 | 47 | 44 | |
| Units: Hours | | | | |
| median (confidence interval 95%) | | | | |
| SpO2 $\geq 92\%$ on Room Air(n=47,47,44) | 95.8 (63.50 to 165.80) | 123.3 (82.00 to 169.10) | 176.5 (77.80 to 309.50) | |
| SpO2 $\geq 95\%$ on Room Air(n=47,47,44) | 95.8 (71.20 to 165.90) | 134.8 (82.00 to 311.50) | 180.5 (85.70 to 315.40) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Percentage of Subjects who Required Supplemental Oxygen

| | |
|-----------------|-----------------------------------------------------------------------------------|
| End point title | Cohort 1: Percentage of Subjects who Required Supplemental Oxygen ^[12] |
|-----------------|-----------------------------------------------------------------------------------|

End point description:

Percentage of subjects who required supplemental oxygen after first dose of study drug was reported. This parameter is only for subjects that did not require oxygen supplementation before first dose of study drug. ITT-i analysis set included all randomised subjects who received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of ≥ 1 log₁₀ copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised. Here, 'N' (number of subjects analysed) signifies number of subjects who were evaluable for this endpoint.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to Day 21

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was planned to be analyzed for specified arms only.

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | |
|-------------------------------|-------------------|---------------------------------|----------------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 14 | 12 | 7 | |
| Units: Percentage of subjects | | | | |
| number (not applicable) | 21.4 | 25.0 | 28.6 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Duration of Supplemental Oxygen

| | |
|-----------------|-----------------------------------------------------------|
| End point title | Cohort 1: Duration of Supplemental Oxygen ^[13] |
|-----------------|-----------------------------------------------------------|

End point description:

Duration of supplemental oxygen was assessed. Duration is defined as total number of hours a subject used supplemental oxygen from first dose of study drug until study termination. ITT-i analysis set included all randomised subjects who received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of ≥ 1 log₁₀ copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised. Here, 'N' (number of subjects analysed) signifies number of subjects who were evaluable for this endpoint.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to Day 21

Notes:

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was planned to be analyzed for specified arms only.

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | |
|-------------------------------|----------------------|---------------------------------|----------------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 34 | 38 | 38 | |
| Units: Hours | | | | |
| median (full range (min-max)) | 74.25 (1.0 to 337.3) | 74.60 (0.2 to 573.5) | 68.05 (1.2 to 348.5) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Percentage of Subjects who Required Non-invasive Mechanical Ventilation Support

| | |
|-----------------|-----------------------------------------------------------------------------------------------------------|
| End point title | Cohort 1: Percentage of Subjects who Required Non-invasive Mechanical Ventilation Support ^[14] |
|-----------------|-----------------------------------------------------------------------------------------------------------|

End point description:

Percentage of subjects who required non-invasive mechanical ventilation support (example: continuous positive airway pressure) after first dose of study drug was reported. This parameter is only for subjects that did not require non-invasive mechanical ventilation support before first dose of study drug (no score was assigned otherwise). ITT-i analysis set included all randomised subjects who received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of ≥ 1 log₁₀ copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised. Here, 'N' (number of subjects analysed) signifies number of subjects who were evaluable for this endpoint.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to Day 21

Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was planned to be analyzed for specified arms only.

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | |
|-------------------------------|-------------------|---------------------------------|----------------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 45 | 44 | 38 | |
| Units: Percentage of subjects | | | | |
| number (not applicable) | 2.2 | 6.8 | 2.6 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Percentage of Subjects who Required Invasive Mechanical Ventilation Support

| | |
|-----------------|-------------------------------------------------------------------------------------------------------|
| End point title | Cohort 1: Percentage of Subjects who Required Invasive Mechanical Ventilation Support ^[15] |
|-----------------|-------------------------------------------------------------------------------------------------------|

End point description:

Percentage of subjects who required invasive mechanical ventilation support (example: endotracheal-mechanical ventilation) after first dose of study drug was reported. This parameter is only for subjects that did not require invasive mechanical ventilation support before first dose of study drug. ITT-i analysis set included all randomised subjects who received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of ≥ 1 log₁₀ copies/mL above the LLOQ of the RSV RT-qPCR

assay at baseline. Analyses on ITT-i set were performed as randomised.

| | |
|----------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Up to Day 21 | |

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was planned to be analyzed for specified arms only.

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | |
|-------------------------------|-------------------|---------------------------------|----------------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 47 | 47 | 44 | |
| Units: Percentage of subjects | | | | |
| number (not applicable) | 4.3 | 2.1 | 2.3 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Percentage of Subjects who Required Non-invasive Non-mechanical Ventilation Support

| | |
|-----------------|---------------------------------------------------------------------------------------------------------------|
| End point title | Cohort 1: Percentage of Subjects who Required Non-invasive Non-mechanical Ventilation Support ^[16] |
|-----------------|---------------------------------------------------------------------------------------------------------------|

End point description:

Percentage of subjects who required non-invasive non-mechanical ventilation support after first dose of study drug was reported. This parameter is only for subjects that did not require non-invasive non-mechanical ventilation support before first dose of study drug. ITT-i analysis set included all randomised subjects who received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of ≥ 1 log₁₀ copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised. Here, 'N' (number of subjects analysed) signifies number of subjects who were evaluable for this endpoint.

| | |
|----------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Up to Day 21 | |

Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was planned to be analyzed for specified arms only.

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | |
|-------------------------------|-------------------|---------------------------------|----------------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 16 | 14 | 11 | |
| Units: Percentage of subjects | | | | |
| number (not applicable) | 31.3 | 35.7 | 45.5 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Duration of Non-invasive Ventilation Support

| | |
|-----------------|------------------------------------------------------------------------|
| End point title | Cohort 1: Duration of Non-invasive Ventilation Support ^[17] |
|-----------------|------------------------------------------------------------------------|

End point description:

Duration of non-invasive ventilation support was not analysed individually due to low number of subjects in some categories hence combined data for 'duration of non-invasive ventilation support' is reported in above endpoint "DURATION OF SUPPLEMENTAL OXYGEN". ITT-i analysis set included all randomised subjects who received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of ≥ 1 log₁₀ copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to Day 21

Notes:

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was planned to be analyzed for specified arms only.

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | |
|-------------------------------|-------------------|---------------------------------|----------------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 0 ^[18] | 0 ^[19] | 0 ^[20] | |
| Units: Hours | | | | |
| median (full range (min-max)) | (to) | (to) | (to) | |

Notes:

[18] - This endpoint was not feasible to analyze individually due to low number of subjects.

[19] - This endpoint was not feasible to analyze individually due to low number of subjects.

[20] - This endpoint was not feasible to analyze individually due to low number of subjects.

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Duration of Invasive Ventilation Support

| | |
|-----------------|--------------------------------------------------------------------|
| End point title | Cohort 1: Duration of Invasive Ventilation Support ^[21] |
|-----------------|--------------------------------------------------------------------|

End point description:

Duration of invasive ventilation support was not analysed individually due to low number of subjects in some categories hence combined data for 'duration of invasive ventilation support' is reported in above outcome measure "duration of supplemental oxygen". ITT-i analysis set included all randomised subjects who received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of ≥ 1 log₁₀ copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to Day 21

Notes:

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was planned to be analyzed for specified arms only.

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | |
|-------------------------------|-------------------|---------------------------------|----------------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 0 ^[22] | 0 ^[23] | 0 ^[24] | |
| Units: Hours | | | | |
| median (full range (min-max)) | (to) | (to) | (to) | |

Notes:

[22] - This endpoint was not analyzed individually due to low number of subjects.

[23] - This endpoint was not analyzed individually due to low number of subjects.

[24] - This endpoint was not analyzed individually due to low number of subjects.

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Time to End of Supplemental Oxygen up to 72 Hours From First Hospital Discharge

| | |
|-----------------|-----------------------------------------------------------------------------------------------------------|
| End point title | Cohort 1: Time to End of Supplemental Oxygen up to 72 Hours From First Hospital Discharge ^[25] |
|-----------------|-----------------------------------------------------------------------------------------------------------|

End point description:

Time to end of supplemental oxygen up to 72 hours from first hospital discharge was assessed. Time to end of supplemental oxygen is defined as time (hours) from first dose of study drug to last end date/time of any oxygen supplementation received, but within 72 hours following first hospital discharge. ITT-i analysis set included all randomised subjects who received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of ≥ 1 log₁₀ copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to 72 hours from first hospital discharge

Notes:

[25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was planned to be analyzed for specified arms only.

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | |
|----------------------------------|-----------------------|---------------------------------|----------------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 47 | 47 | 44 | |
| Units: Hours | | | | |
| median (confidence interval 95%) | 58.1 (22.90 to 75.90) | 57.9 (35.30 to 85.50) | 63.0 (31.80 to 92.00) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort 1: Percentage of Subjects who Needed Hydration and/or Feeding by Intravenous (IV) Administration or Nasogastric Tube

| | |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Cohort 1: Percentage of Subjects who Needed Hydration and/or Feeding by Intravenous (IV) Administration or Nasogastric Tube ^[26] |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Percentage of subjects who needed hydration and/or feeding by IV Administration or nasogastric tube after the first dose of study drug was reported. This parameter is only for subjects who didn't require supplemental feeding/hydration before first dose of study drug. ITT-i analysis set included all randomised subjects who received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of $\geq 1 \log_{10}$ copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised. Here, 'N' (number of subjects analysed) signifies number of subjects who were evaluable for this endpoint.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to Day 28

Notes:

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was planned to be analyzed for specified arms only.

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | |
|-------------------------------|-------------------|---------------------------------|----------------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 32 | 32 | 26 | |
| Units: percentage of subjects | | | | |
| number (not applicable) | 6.3 | 15.6 | 19.2 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects with Adverse Events

| | |
|-----------------|--------------------------------------------|
| End point title | Percentage of Subjects with Adverse Events |
|-----------------|--------------------------------------------|

End point description:

Percentage of subjects with adverse events was reported. An AE is any untoward medical occurrence in clinical study subjects administered a medicinal (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the intervention. The Safety analysis set included all subjects who received at least 1 dose of study agent, and were analysed as treated, regardless of the randomised treatment group assigned.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to Day 28

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | Cohort 2: Placebo |
|-------------------------------|-------------------|---------------------------------|----------------------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 50 | 49 | 48 | 34 |
| Units: Percentage of subjects | | | | |
| number (not applicable) | 58.0 | 59.2 | 64.6 | 47.1 |

| End point values | Cohort 2: JNJ-53718678 Low Dose | Cohort 2: JNJ-53718678 High Dose | | |
|-------------------------------|---------------------------------|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 34 | 31 | | |
| Units: Percentage of subjects | | | | |
| number (not applicable) | 58.8 | 41.9 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects with Abnormal Laboratory Findings

| | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------|
| End point title | Percentage of Subjects with Abnormal Laboratory Findings |
| End point description: | |
| Percentage of subjects with abnormal laboratory findings (chemistry and hematology) worst toxicity grade were reported based on Division of Microbiology and Infectious Diseases (DMID) toxicity grading scale. DMID toxicity grades ranges from 1 to 4. Grade 1=mild: transient or mild discomfort (<48 hours); no medical intervention/therapy required. Grade 2 = moderate: no or minimal medical intervention/therapy required. Grade 3 = severe: medical intervention/therapy required, hospitalizations possible. Grade 4 = life-threatening or death. The Safety analysis set included all subjects who received at least 1 dose of study agent, and were analysed as treated, regardless of the randomised treatment group assigned. Here, 'n' (number analysed) represents number of subjects evaluable at the specified timepoints. Here, 99999 indicates no subjects identified as complying with the grade-level pre-defined criterion. | |
| End point type | Secondary |
| End point timeframe: | |
| Up to Day 28 | |

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | Cohort 2: Placebo |
|----------------------------------------------------|-------------------|---------------------------------|----------------------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 50 | 49 | 48 | 34 |
| Units: percentage of subjects | | | | |
| number (not applicable) | | | | |
| Chemistry: ALT: Grade 1 (n=22, 27, 22, 32, 28, 29) | 13.6 | 0 | 0 | 0 |
| Chemistry: ALT: Grade 2 (n=22, 27, 22, 0, 0, 0) | 0 | 0 | 4.5 | 99999 |
| Chemistry: ALT: Grade 3 (n=22, 27, 22, 0, 0, 0) | 4.5 | 0 | 0 | 99999 |
| Chemistry: AST: Grade 1 (n=22, 25, 22, 31, 29, 30) | 0 | 0 | 4.5 | 0 |
| Chemistry: AST: Grade 3 (n=22, 25, 22, 0, 0, 0) | 4.5 | 0 | 0 | 99999 |
| Chemistry:Hyperbilirubinemia:G-2(n=37,37,34,0,0,0) | 2.7 | 0 | 0 | 99999 |

| | | | | |
|---------------------------------------------------|-------|-------|-------|-------|
| Chemistry:Hyperglycemia:G-1(n=22,26,23,32,29,30) | 13.6 | 0 | 4.3 | 6.3 |
| Chemistry:Hyperkalemia:G-1(n=22,27,23,32,29,30) | 59.1 | 22.2 | 39.1 | 21.9 |
| Chemistry:Hyperkalemia:G-2(n=22,27,23,32,29,30) | 0 | 0 | 4.3 | 3.1 |
| Chemistry:Hyperkalemia:G-4(n=22,27,23,0,0,0) | 0 | 0 | 8.7 | 99999 |
| Chemistry:Hypernatremia:G-2(n=22,27,23,32,29,30) | 4.5 | 3.7 | 0 | 3.1 |
| Chemistry:Hypernatremia:G-3(n=22,27,23,0,0,0) | 4.5 | 0 | 0 | 99999 |
| Chemistry:Hyperuricemia:G-1(n=22,27,23,0,0,0) | 0 | 0 | 4.3 | 99999 |
| Chemistry:Hypoglycemia:G-1(n=22,26,23,32,29,30) | 4.5 | 0 | 4.3 | 6.3 |
| Chemistry:Hypomagnesemia:G-1(n=22,27,23,32,29,30) | 0 | 3.7 | 4.3 | 3.1 |
| Chemistry:Hypomagnesemia:G-2(n=22,27,23,0,0,0) | 0 | 0 | 4.3 | 99999 |
| Chemistry:Hypomagnesemia:G-3(n=22,27,23,0,0,0) | 0 | 0 | 4.3 | 99999 |
| Chemistry:Hyponatremia:G-2(n=22,27,23,32,29,30) | 4.5 | 3.7 | 0 | 0 |
| Hematology:ANC: G-1(n=37,35,36,33,33,28) | 13.5 | 11.4 | 2.8 | 3.0 |
| Hematology: ANC: G-3 (n=37,35,36,0,0,0) | 0 | 2.9 | 0 | 99999 |
| Hematology: APTT: Grade 1(n=9,10,15,1,3,3) | 11.1 | 0 | 0 | 0 |
| Hematology: Hemoglobin: Grade 1(n=38,36,35,0,0,0) | 7.9 | 5.6 | 2.9 | 99999 |
| Hematology: Hemoglobin: Grade 2(n=38,36,35,0,0,0) | 2.6 | 2.8 | 0 | 99999 |
| Hematology:Prothrombin Time:G-1(n=38,36,35,0,0,0) | 0 | 10.0 | 0 | 99999 |
| Hematology:Prothrombin Time:G-3(n=38,36,35,0,0,0) | 11.1 | 0 | 6.7 | 99999 |
| Chemistry:Hyperglycemia:G-2(n=0,0,0,32,29,30) | 99999 | 99999 | 99999 | 0 |

| End point values | Cohort 2: JNJ-53718678 Low Dose | Cohort 2: JNJ-53718678 High Dose | | |
|----------------------------------------------------|---------------------------------|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 34 | 31 | | |
| Units: percentage of subjects | | | | |
| number (not applicable) | | | | |
| Chemistry: ALT: Grade 1 (n=22, 27, 22, 32, 28, 29) | 3.6 | 3.4 | | |
| Chemistry: ALT: Grade 2 (n=22, 27, 22, 0, 0, 0) | 99999 | 99999 | | |
| Chemistry: ALT: Grade 3 (n=22, 27, 22, 0, 0, 0) | 99999 | 99999 | | |
| Chemistry: AST: Grade 1 (n=22, 25, 22, 31, 29, 30) | 0 | 3.3 | | |
| Chemistry: AST: Grade 3 (n=22, 25, 22, 0, 0, 0) | 99999 | 99999 | | |

| | | | | |
|----------------------------------------------------|-------|-------|--|--|
| Chemistry:Hyperbilirubinemia:G-2(n=37,37,34,0,0,0) | 99999 | 99999 | | |
| Chemistry:Hyperglycemia:G-1(n=22,26,23,32,29,30) | 3.4 | 10.0 | | |
| Chemistry:Hyperkalemia:G-1(n=22,27,23,32,29,30) | 55.2 | 36.7 | | |
| Chemistry:Hyperkalemia:G-2(n=22,27,23,32,29,30) | 3.4 | 3.3 | | |
| Chemistry:Hyperkalemia:G-4(n=22,27,23,0,0,0) | 99999 | 99999 | | |
| Chemistry:Hypernatremia:G-2(n=22,27,23,32,29,30) | 3.4 | 3.3 | | |
| Chemistry:Hypernatremia:G-3(n=22,27,23,0,0,0) | 99999 | 99999 | | |
| Chemistry:Hyperuricemia:G-1(n=22,27,23,0,0,0) | 99999 | 99999 | | |
| Chemistry:Hypoglycemia:G-1(n=22,26,23,32,29,30) | 3.4 | 0 | | |
| Chemistry:Hypomagnesemia:G-1(n=22,27,23,32,29,30) | 0 | 0 | | |
| Chemistry:Hypomagnesemia:G-2(n=22,27,23,0,0,0) | 99999 | 99999 | | |
| Chemistry:Hypomagnesemia:G-3(n=22,27,23,0,0,0) | 99999 | 99999 | | |
| Chemistry:Hyponatremia:G-2(n=22,27,23,32,29,30) | 0 | 10.0 | | |
| Hematology:ANC: G-1(n=37,35,36,33,33,28) | 9.1 | 0 | | |
| Hematology: ANC: G-3(n=37,35,36,0,0,0) | 99999 | 99999 | | |
| Hematology: APTT: Grade 1(n=9,10,15,1,3,3) | 0 | 33.3 | | |
| Hematology: Hemoglobin: Grade 1(n=38,36,35,0,0,0) | 99999 | 99999 | | |
| Hematology: Hemoglobin: Grade 2(n=38,36,35,0,0,0) | 99999 | 99999 | | |
| Hematology:Prothrombin Time:G-1(n=38,36,35,0,0,0) | 99999 | 99999 | | |
| Hematology:Prothrombin Time:G-3(n=38,36,35,0,0,0) | 99999 | 99999 | | |
| Chemistry:Hyperglycemia:G-2(n=0,0,0,32,29,30) | 0 | 3.3 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Abnormal Electrocardiograms (ECGs) Findings

| | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| End point title | Percentage of Subjects With Abnormal Electrocardiograms (ECGs) Findings |
| End point description: Percentage of subjects with abnormal ECG (PR interval, RR interval, QT interval, QRS duration) findings was reported. The Safety analysis set included all subjects who received at least 1 dose of study agent, and were analysed as treated, regardless of the randomised treatment group assigned. Here, 'n' (number analysed) represents number of subjects evaluable at the specified categories (per ECG parameters). | |
| End point type | Secondary |

End point timeframe:

Up to Day 28

| End point values | Cohort 1: Placebo | Cohort 1: JNJ- 53718678 Low Dose | Cohort 1: JNJ- 53718678 High Dose | Cohort 2: Placebo |
|-------------------------------------------------------|----------------------|----------------------------------------|-----------------------------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 50 | 49 | 48 | 34 |
| Units: percentage of subjects | | | | |
| number (not applicable) | | | | |
| QRS Duration: Abnormally High(n=49,48,48,33,33,31) | 4.1 | 4.2 | 4.2 | 6.1 |
| RR Interval: Abnormally Low(n=49,48,48,33,33,31) | 12.2 | 8.3 | 12.5 | 21.2 |
| PR Interval: Abnormally Low(n=49,48,48,33,33,31) | 0 | 2.1 | 2.1 | 0 |
| QT Interval: Abnormally Low(n=49,48,48,33,33,31) | 2.0 | 4.2 | 2.1 | 3.0 |

| End point values | Cohort 2: JNJ- 53718678 Low Dose | Cohort 2: JNJ- 53718678 High Dose | | |
|-------------------------------------------------------|----------------------------------------|-----------------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 34 | 31 | | |
| Units: percentage of subjects | | | | |
| number (not applicable) | | | | |
| QRS Duration: Abnormally High(n=49,48,48,33,33,31) | 6.1 | 9.7 | | |
| RR Interval: Abnormally Low(n=49,48,48,33,33,31) | 15.2 | 9.7 | | |
| PR Interval: Abnormally Low(n=49,48,48,33,33,31) | 3.0 | 0 | | |
| QT Interval: Abnormally Low(n=49,48,48,33,33,31) | 9.1 | 3.2 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects with Categorized Change from Baseline in ECG Parameters (QT/ QTc)

| | |
|-----------------|------------------------------------------------------------------------------------------|
| End point title | Percentage of Subjects with Categorized Change from Baseline in ECG Parameters (QT/ QTc) |
|-----------------|------------------------------------------------------------------------------------------|

End point description:

Percentage of subjects with categorized change from Baseline in ECG parameters (QT/ QTc interval) was assessed. Parameters for abnormal ECG findings were QT interval corrected for heart rate (QTc) according to Bazett's formula (QTcB) Interval ([450 milliseconds {ms}, 480 ms], [480 ms, 500 ms], and [more than 500 ms]), QTc according to Fridericia's formula (QTcF) Interval ([450 ms, 480 ms], [480 ms, 500 ms], and [more than 500 ms]), change from baseline for QTcB Interval ([30; 60] ms, and

greater than [$>$] 60 ms), and for QTcF Interval ([30; 60] ms, and >60 ms). The Safety analysis set included all subjects who received at least 1 dose of study agent, and were analysed as treated, regardless of the randomised treatment group assigned. Here, 'n' (number analysed) represents number of subjects evaluable per ECG parameter.

| | |
|----------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Baseline to Day 28 | |

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | Cohort 2: Placebo |
|----------------------------------------------------|-------------------|---------------------------------|----------------------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 50 | 49 | 48 | 34 |
| Units: Percentage of subjects | | | | |
| number (not applicable) | | | | |
| QT Interval:Normal QTc change(n=48,48,48,33,33,29) | 66.7 | 70.8 | 68.8 | 66.7 |
| QT Interval:Borderline QTc (n=48,48,48,33,33,29) | 29.2 | 25.0 | 27.1 | 27.3 |
| QT Interval:AbnormallyhighQTc(n=48,48,4 | 4.2 | 4.2 | 4.2 | 6.1 |
| QTcB Interval:Normal QTc(n=48,48,48,33,33,29) | 83.8 | 87.5 | 93.8 | 90.9 |
| QTcB Interval:Borderline QTc(n=48,48,48,33,33,29) | 14.6 | 12.5 | 6.3 | 9.1 |
| QTcB: Abnormally high QTc(n=48,48,48,33,33,29) | 2.1 | 0 | 0 | 0 |
| QTcF Interval:Normal QTc(n=48,48,48,33,33,29) | 81.3 | 83.3 | 83.3 | 90.9 |
| QTcF Interval:Borderline QTc(n=48,48,48,33,33,29) | 16.7 | 16.7 | 16.7 | 9.1 |
| QTcF: Abnormally high QTc(n=48,48,48,33,33,29) | 2.1 | 0 | 0 | 0 |

| End point values | Cohort 2: JNJ-53718678 Low Dose | Cohort 2: JNJ-53718678 High Dose | | |
|----------------------------------------------------|---------------------------------|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 34 | 31 | | |
| Units: Percentage of subjects | | | | |
| number (not applicable) | | | | |
| QT Interval:Normal QTc change(n=48,48,48,33,33,29) | 57.6 | 58.6 | | |
| QT Interval:Borderline QTc (n=48,48,48,33,33,29) | 33.3 | 37.9 | | |
| QT Interval:AbnormallyhighQTc(n=48,48,4 | 9.1 | 3.4 | | |
| QTcB Interval:Normal QTc(n=48,48,48,33,33,29) | 90.9 | 93.1 | | |
| QTcB Interval:Borderline QTc(n=48,48,48,33,33,29) | 9.1 | 6.9 | | |
| QTcB: Abnormally high QTc(n=48,48,48,33,33,29) | 0 | 0 | | |

| | | | | |
|------------------------------------------------------|------|------|--|--|
| QTcF Interval:Normal QTc(n=48,48,48,33,33,29) | 78.8 | 86.3 | | |
| QTcF Interval:Borderline QTc(n=48,48,48,33,33,29) | 21.2 | 13.8 | | |
| QTcF: Abnormally high QTc(n=48,48,48,33,33,29) | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Vital Signs Abnormalities

| | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|
| End point title | Percentage of Subjects With Vital Signs Abnormalities |
| End point description: | |
| Percentage of subjects with vital signs (systolic blood pressure [SBP], diastolic blood pressure [DBP], pulse rate, respiratory rate [RR], body temperature and SpO2) abnormalities (abnormally low [ABL] and abnormally high [ABH]) were reported. The Safety analysis set included all subjects who received at least 1 dose of study agent, and were analysed as treated, regardless of the randomised treatment group assigned. Here, 'n' (number analysed) represents number of subjects evaluable per vital signs parameter. Here, 99999 indicates no subjects identified as complying with the grade-level pre-defined criterion. | |
| End point type | Secondary |
| End point timeframe: | |
| Up to Day 28 | |

| End point values | Cohort 1: Placebo | Cohort 1: JNJ- 53718678 Low Dose | Cohort 1: JNJ- 53718678 High Dose | Cohort 2: Placebo |
|---------------------------------------------------|----------------------|----------------------------------------|-----------------------------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 50 | 49 | 48 | 34 |
| Units: percentage of subjects | | | | |
| number (not applicable) | | | | |
| SBP:AbnormallyLow(n=49,48,48,33,34,31) | 2.0 | 2.1 | 8.3 | 12.1 |
| SBP:AbnormallyHigh(n=49,48,48,33,34,31) | 42.9 | 45.8 | 35.4 | 18.2 |
| DBP:AbnormallyLow(n=49,48,48,33,34,31) | 8.2 | 18.8 | 25.0 | 15.2 |
| DBP:AbnormallyHigh(n=49,48,48,33,34,31) | 28.6 | 35.4 | 27.1 | 9.1 |
| Pulse rate: Abnormally High(n=49,48,48,33,34,31) | 30.6 | 27.1 | 27.1 | 12.1 |
| Pulse rate: Abnormally Low(n=49,48,48,33,34,31) | 0.0 | 2.1 | 0 | 6.1 |
| RR:Abnormally High(n=49,48,48,34,34,31) | 4.1 | 12.5 | 18.8 | 3.1 |
| RR:Abnormally Low(n=49,48,48,0,0,0) | 12.2 | 10.4 | 0.0 | 99999 |
| Temperature: Abnormally High(n=49,48,48,34,34,31) | 30.6 | 41.7 | 22.9 | 50.0 |
| SpO2:Abnormally Low(n=49,48,48,32,32,30) | 8.2 | 12.5 | 6.3 | 3.1 |

| End point values | Cohort 2: JNJ-53718678 Low Dose | Cohort 2: JNJ-53718678 High Dose | | |
|---------------------------------------------------|---------------------------------|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 34 | 31 | | |
| Units: percentage of subjects | | | | |
| number (not applicable) | | | | |
| SBP:AbnormallyLow(n=49,48,48,33,34,31) | 8.8 | 9.7 | | |
| SBP:AbnormallyHigh(n=49,48,48,33,34,31) | 17.6 | 12.9 | | |
| DBP:AbnormallyLow(n=49,48,48,33,34,31) | 2.9 | 0 | | |
| DBP:AbnormallyHigh(n=49,48,48,33,34,31) | 17.6 | 6.5 | | |
| Pulse rate: Abnormally High(n=49,48,48,33,34,31) | 20.6 | 16.1 | | |
| Pulse rate: Abnormally Low(n=49,48,48,33,34,31) | 5.9 | 16.1 | | |
| RR:Abnormally High(n=49,48,48,34,34,31) | 2.9 | 6.5 | | |
| RR:Abnormally Low(n=49,48,48,0,0,0) | 99999 | 99999 | | |
| Temperature: Abnormally High(n=49,48,48,34,34,31) | 52.9 | 54.8 | | |
| SpO2:Abnormally Low(n=49,48,48,32,32,30) | 9.4 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under the Plasma Concentration-Time Curve From Timepoint 0 Hours Until 24 Hours Post Dose (AUC[0-24 hours])

| | |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------|
| End point title | Area Under the Plasma Concentration-Time Curve From Timepoint 0 Hours Until 24 Hours Post Dose (AUC[0-24 hours]) ^[27] |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------|

End point description:

AUC (0-24) is defined as area under the plasma concentration-time curve from timepoint 0 hours until 24 hours post dose. This endpoint was not analysed for Cohort 2 due to premature study termination. Pharmacokinetic (PK) analysis set included all subjects who received JNJ-53718678 and for whom at least one PK concentration was reported. Here, 'n' (number analysed) represents number of subjects evaluable at the specified timepoints.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

0 to 24 hours post dose on Days 1 and 7

Notes:

[27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was planned to be analyzed for specified arms only.

| End point values | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | | |
|-------------------------------------------------|---------------------------------|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 30 | 32 | | |
| Units: nanograms*hours per millilitre (ng*h/mL) | | | | |
| arithmetic mean (standard deviation) | | | | |
| >=28 days and <3 months: Day 1 (n=6,7) | 6690 (± 1950) | 20600 (± 3990) | | |
| >=28 days and <3 months: Day 7 (n=6,7) | 11400 (± 3930) | 36000 (± 8140) | | |
| >=3 months and <6 months: Day 1 (n=6,4) | 5340 (± 2670) | 23600 (± 12500) | | |
| >=3 months and <6 months: Day 7 (n=6,4) | 7370 (± 4270) | 35000 (± 20100) | | |
| >=6 months and <=3 years: Day 1 (n=11,17) | 6910 (± 2900) | 25000 (± 11600) | | |
| >=6 months and <=3 years: Day 7 (n=11,17) | 8160 (± 3950) | 31000 (± 16300) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum Plasma Concentration (Cmax) of JNJ-53718678

| | |
|-----------------|---------------------------------------------------------------------|
| End point title | Maximum Plasma Concentration (Cmax) of JNJ-53718678 ^[28] |
|-----------------|---------------------------------------------------------------------|

End point description:

Cmax is the maximum plasma concentration of JNJ-53718678 estimated by population PK model. This endpoint was not analysed for Cohort 2 due to premature study termination. PK analysis set included all subjects who received JNJ-53718678 and for whom at least one PK concentration was reported. Here, 'n' (number analysed) represents number of subjects evaluable at the specified timepoints.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 1 and 7

Notes:

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was planned to be analyzed for specified arms only.

| End point values | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | | |
|------------------------------------------|---------------------------------|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 30 | 32 | | |
| Units: nanograms per millilitre (ng/mL) | | | | |
| arithmetic mean (standard deviation) | | | | |
| >=28 days and <3 months: Day 1 (n=6, 7) | 531 (± 193) | 1590 (± 345) | | |
| >=28 days and <3 months: Day 7 (n=6, 7) | 843 (± 255) | 2550 (± 550) | | |
| >=3 months and <6 months: Day 1 (n=6, 4) | 497 (± 256) | 2070 (± 1200) | | |

| | | | | |
|-----------------------------------------------|--------------|---------------|--|--|
| >=3 months and <6 months: Day 7 (n=6, 4) | 691 (± 306) | 2920 (± 1500) | | |
| >=6 months and <=3 years: Day 1 (n=12, 18) | 846 (± 268) | 2720 (± 1040) | | |
| >=6 months and <=3 years: Day 7 (n=11, 17) | 1030 (± 310) | 3560 (± 1330) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Trough Plasma Concentration (Ctrough) of JNJ-53718678

| | |
|-----------------|-----------------------------------------------------------------------|
| End point title | Trough Plasma Concentration (Ctrough) of JNJ-53718678 ^[29] |
|-----------------|-----------------------------------------------------------------------|

End point description:

Ctrough is the trough plasma concentration of JNJ-53718678 estimated by population PK model. This endpoint was not analysed for Cohort 2 due to premature study termination. PK analysis set included all subjects who received JNJ-53718678 and for whom at least one PK concentration was reported. Here, 'n' (number analysed) represents number of subjects evaluable at the specified timepoints.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 1 and 7

Notes:

[29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was planned to be analyzed for specified arms only.

| End point values | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | | |
|-----------------------------------------------|---------------------------------|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 30 | 32 | | |
| Units: ng/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| >=28 days and <3 months: Day 1 (n=6, 7) | 64 (± 31.3) | 167 (± 147) | | |
| >=28 days and <3 months: Day 7 (n=6, 7) | 267 (± 111) | 885 (± 239) | | |
| >=3 months and <6 months: Day 1 (n=6, 4) | 55.5 (± 33.5) | 204 (± 58.5) | | |
| >=3 months and <6 months: Day 7 (n=6, 4) | 126 (± 103) | 702 (± 487) | | |
| >=6 months and <=3 years: Day 1 (n=11, 17) | 59.9 (± 43) | 227 (± 149) | | |
| >=6 months and <=3 years: Day 7 (n=11, 17) | 89 (± 73.6) | 386 (± 331) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Medical Resource Utilization (MRU)

| | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|
| End point title | Percentage of Subjects With Medical Resource Utilization (MRU) |
| End point description: | |
| Percentage of subjects with MRU (any medical care encounters) were reported. MRU was assessed by the number, frequency and type of medical care encounters, including for RSV infection or RSV-related complications, based on investigator assessment. ITT-i analysis set included all randomised subjects who received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of ≥ 1 log ₁₀ copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised. Here, 'N' (number of subjects analysed) signifies number of subjects who were evaluable for this endpoint. | |
| End point type | Secondary |
| End point timeframe: | |
| Up to Day 28 | |

| End point values | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose | Cohort 2: Placebo |
|-------------------------------|-------------------|---------------------------------|----------------------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 38 | 36 | 37 | 32 |
| Units: percentage of subjects | | | | |
| number (not applicable) | 23.7 | 13.9 | 21.6 | 9.4 |

| End point values | Cohort 2: JNJ-53718678 Low Dose | Cohort 2: JNJ-53718678 High Dose | | |
|-------------------------------|---------------------------------|----------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 33 | 28 | | |
| Units: percentage of subjects | | | | |
| number (not applicable) | 15.2 | 25.0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects with Acceptability and Palatability of the JNJ-53718678 Formulation as Assessed by Parent(s)/Caregiver(s)

| | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Subjects with Acceptability and Palatability of the JNJ-53718678 Formulation as Assessed by Parent(s)/Caregiver(s) |
| End point description: | |
| Percentage of subjects with acceptability and palatability of the JNJ-53718678 formulation were assessed through a questionnaire asking about the child's reaction when given the medicine, completed by parent(s)/caregiver(s) after last dosing. ITT-i analysis set included all randomised subjects who received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of ≥ 1 log ₁₀ copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised. Here, 'N' (number of subjects analysed) signifies number of subjects who were evaluable for this endpoint. | |
| End point type | Secondary |
| End point timeframe: | |
| Day 8 | |

| End point values | Cohort 1: Placebo | Cohort 1: JNJ- 53718678 Low Dose | Cohort 1: JNJ- 53718678 High Dose | Cohort 2: Placebo |
|-------------------------------|----------------------|----------------------------------------|-----------------------------------------|----------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 34 | 32 | 37 | 24 |
| Units: percentage of subjects | | | | |
| number (not applicable) | 67.6 | 84.4 | 73.0 | 70.8 |

| End point values | Cohort 2: JNJ- 53718678 Low Dose | Cohort 2: JNJ- 53718678 High Dose | | |
|-------------------------------|----------------------------------------|-----------------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 21 | 21 | | |
| Units: percentage of subjects | | | | |
| number (not applicable) | 90.5 | 85.7 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects with Emerging Variations in the Viral Genome Potentially Associated with Resistance to JNJ-53718678

| | |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Number of Subjects with Emerging Variations in the Viral Genome Potentially Associated with Resistance to JNJ-53718678 ^[30] |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Number of subjects with F gene sequencing data available and with emerging genetic variations post-baseline as compared to baseline, considering 24 RSV F protein positions of interest (positions 127, 137, 138, 140, 141, 143, 144, 323, 338, 339, 392, 394, 396, 397, 398, 399, 400, 401, 474, 486, 487, 488, 489, and 517) was reported. This endpoint was not analysed for Cohort 2 due to premature study termination. ITT-i analysis set included all randomised subjects who received at least one dose of study drug and who had centrally confirmed RSV RNA viral load of ≥ 1 log₁₀ copies/mL above the LLOQ of the RSV RT-qPCR assay at baseline. Analyses on ITT-i set were performed as randomised. Here, 'N' (number of subjects analysed) signifies number of subjects who were evaluable for this endpoint.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to Day 21

Notes:

[30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was planned to be analyzed for specified arms only.

| End point values | Cohort 1: Placebo | Cohort 1: JNJ- 53718678 Low Dose | Cohort 1: JNJ- 53718678 High Dose | |
|-----------------------------|----------------------|----------------------------------------|-----------------------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 44 | 43 | 40 | |
| Units: Subjects | 0 | 0 | 2 | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to Day 28

Adverse event reporting additional description:

The safety analysis set included all subjects who received at least 1 dose of study agent, and were analysed as treated, regardless of the randomised treatment group assigned.

| | |
|-----------------|----------------|
| Assessment type | Non-systematic |
|-----------------|----------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|----------|
| Dictionary version | 23.124.1 |
|--------------------|----------|

Reporting groups

| | |
|-----------------------|-------------------|
| Reporting group title | Cohort 1: Placebo |
|-----------------------|-------------------|

Reporting group description:

Subjects of age groups (age group 1: greater than or equal to [\geq] 28 days to less than [$<$] 3 months, age group 2: \geq 3 months to $<$ 6 months, and age group 3: \geq 6 months to less than or equal to [\leq] 3 years), who were hospitalized or expected to be hospitalized within 24 hours after presentation to the hospital received placebo matching to JNJ-53718678 (high volume placebo or low volume placebo to match the calculated volume of the JNJ-53718678 for the high dose or low dose, respectively) orally once daily for 7 days.

| | |
|-----------------------|---------------------------------|
| Reporting group title | Cohort 1: JNJ-53718678 Low Dose |
|-----------------------|---------------------------------|

Reporting group description:

Subjects who were hospitalized or expected to be hospitalized within 24 hours after presentation to the hospital received JNJ-53718678 1.7 milligrams per kilogram (mg/kg) for age group 1: \geq 28 days to $<$ 3 months; 2 mg/kg for age group 2: \geq 3 months to $<$ 6 months; and 3 mg/kg for age group 3: \geq 6 months to \leq 3 years, orally once daily for 7 days.

| | |
|-----------------------|----------------------------------|
| Reporting group title | Cohort 2: JNJ-53718678 High Dose |
|-----------------------|----------------------------------|

Reporting group description:

As per the original dosing, outpatient subjects were randomised to receive JNJ-53718678 5 mg/kg for age group 1: \geq 28 days to $<$ 3 months; 6 mg/kg for age group 2: \geq 3 months to $<$ 6 months; and 9 mg/kg for age group 3: \geq 6 months to \leq 3 years, orally once daily for 7 days. After protocol amendment 4, subjects were randomised to receive JNJ-53718678 2.5 mg/kg for age group 1, JNJ-53718678 3.0 mg/kg for age group 2, and JNJ-53718678 4.5 mg/kg for age group 3, orally twice daily for 7 days.

| | |
|-----------------------|-------------------|
| Reporting group title | Cohort 2: Placebo |
|-----------------------|-------------------|

Reporting group description:

As per the original dosing, outpatient subjects of age groups (age group 1: \geq 28 days to $<$ 3 months, age group 2: \geq 3 months to $<$ 6 months, and age group 3: \geq 6 months to \leq 3 years) were randomised to receive placebo matching to JNJ-53718678 (high volume placebo or low volume placebo to match the calculated volume of the JNJ-53718678 for the high dose or low dose, respectively) orally once daily for 7 days. After Protocol amendment 4, subjects were randomised to receive placebo matching to JNJ-53718678 orally twice daily for 7 days.

| | |
|-----------------------|---------------------------------|
| Reporting group title | Cohort 2: JNJ-53718678 Low Dose |
|-----------------------|---------------------------------|

Reporting group description:

As per the original dosing, outpatients subjects were randomised to receive JNJ-53718678 1.7 mg/kg for age group 1: \geq 28 days to $<$ 3 months; 2 mg/kg for age group 2: \geq 3 months to $<$ 6 months; and 3 mg/kg for age group 3: \geq 6 months to \leq 3 years, orally once daily for 7 days. After protocol amendment 4, subjects were randomised to receive JNJ-53718678 0.85 mg/kg for age group 1, JNJ-53718678 1.0 mg/kg for age group 2, and JNJ-53718678 1.5 mg/kg for age group 3, orally twice daily for 7 days.

| | |
|-----------------------|----------------------------------|
| Reporting group title | Cohort 1: JNJ-53718678 High Dose |
|-----------------------|----------------------------------|

Reporting group description:

Subjects who were hospitalized or expected to be hospitalized within 24 hours after presentation to the hospital received JNJ-53718678 5 mg/kg for age group 1: \geq 28 days to $<$ 3 months; 6 mg/kg for age group 2: \geq 3 months to $<$ 6 months; and 9 mg/kg for age group 3: \geq 6 months to \leq 3 years, orally once daily for 7 days.

| Serious adverse events | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 2: JNJ-53718678 High Dose |
|---------------------------------------------------|-------------------|---------------------------------|----------------------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 4 / 50 (8.00%) | 5 / 49 (10.20%) | 3 / 31 (9.68%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Acute Respiratory Failure | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 49 (2.04%) | 0 / 31 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Asthma | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 1 / 31 (3.23%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypoxia | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory Failure | | | |
| subjects affected / exposed | 2 / 50 (4.00%) | 1 / 49 (2.04%) | 0 / 31 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Wheezing | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Bronchiolitis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchitis | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 49 (2.04%) | 1 / 31 (3.23%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Coronavirus Infection | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 1 / 31 (3.23%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia Respiratory Syncytial Viral | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory Syncytial Virus Bronchiolitis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 49 (2.04%) | 0 / 31 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory Tract Infection | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 49 (2.04%) | 0 / 31 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| Feeding Disorder | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 49 (2.04%) | 0 / 31 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Cohort 2: Placebo | Cohort 2: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose |
|---------------------------------------------------|-------------------|---------------------------------|----------------------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 2 / 34 (5.88%) | 2 / 34 (5.88%) | 2 / 48 (4.17%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Acute Respiratory Failure | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Asthma | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypoxia | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory Failure | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 1 / 48 (2.08%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Wheezing | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 34 (2.94%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Bronchiolitis | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Coronavirus Infection | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 34 (2.94%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 1 / 48 (2.08%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia Respiratory Syncytial Viral | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 34 (2.94%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory Syncytial Virus Bronchiolitis | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory Tract Infection | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Feeding Disorder | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

Frequency threshold for reporting non-serious adverse events: 0 %

| Non-serious adverse events | Cohort 1: Placebo | Cohort 1: JNJ-53718678 Low Dose | Cohort 2: JNJ-53718678 High Dose |
|-------------------------------------------------------|-------------------|---------------------------------|----------------------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 28 / 50 (56.00%) | 29 / 49 (59.18%) | 13 / 31 (41.94%) |
| Vascular disorders | | | |
| Haematoma | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hyperaemia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| General disorders and administration site conditions | | | |
| Face Oedema | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hyperthermia | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Oedema Peripheral | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pyrexia | | | |
| subjects affected / exposed | 2 / 50 (4.00%) | 3 / 49 (6.12%) | 1 / 31 (3.23%) |
| occurrences (all) | 2 | 3 | 1 |
| Respiratory, thoracic and mediastinal | | | |

| | | | |
|-------------------------------|----------------|----------------|----------------|
| disorders | | | |
| Asthma | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 1 / 31 (3.23%) |
| occurrences (all) | 0 | 0 | 1 |
| Atelectasis | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 1 / 49 (2.04%) | 0 / 31 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Bronchial Obstruction | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bronchial Secretion Retention | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Bronchospasm | | | |
| subjects affected / exposed | 2 / 50 (4.00%) | 1 / 49 (2.04%) | 0 / 31 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Catarrh | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 49 (2.04%) | 1 / 31 (3.23%) |
| occurrences (all) | 0 | 1 | 1 |
| Cough | | | |
| subjects affected / exposed | 2 / 50 (4.00%) | 1 / 49 (2.04%) | 1 / 31 (3.23%) |
| occurrences (all) | 2 | 1 | 1 |
| Dysphonia | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Lung Consolidation | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Epistaxis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasal Discomfort | | | |

| | | | |
|--------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 49 (2.04%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Respiratory Depth Increased | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 49 (2.04%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Respiratory Distress | | | |
| subjects affected / exposed | 2 / 50 (4.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Rhinorrhoea | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus Disorder | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper Respiratory Tract Congestion | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Upper Respiratory Tract Inflammation | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Wheezing | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 49 (2.04%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Psychiatric disorders | | | |
| Restlessness | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Investigations | | | |
| Alanine Aminotransferase Increased | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Aspartate Aminotransferase Increased | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood Creatinine Increased | | | |

| | | | |
|------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood Potassium Increased | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 49 (2.04%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Oxygen Saturation Decreased | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 49 (2.04%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Platelet Count Increased | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 49 (2.04%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Transaminases Increased | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Injury, poisoning and procedural complications | | | |
| Arthropod Sting | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Contusion | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 1 / 49 (2.04%) | 0 / 31 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Head Injury | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin Wound | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 49 (2.04%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Radial Head Dislocation | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 49 (2.04%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 2 / 49 (4.08%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Eosinophilia | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Leukopenia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 49 (2.04%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Lymphocytosis | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 1 / 49 (2.04%) | 0 / 31 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Lymphadenopathy | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Neutropenia | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Thrombocytosis | | | |
| subjects affected / exposed | 2 / 50 (4.00%) | 2 / 49 (4.08%) | 0 / 31 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Eye disorders | | | |
| Eye Discharge | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 49 (2.04%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Ocular Hyperaemia | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal disorders | | | |
| Anorectal Discomfort | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anal Erythema | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 49 (2.04%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Constipation | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 49 (2.04%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Faeces Soft | | | |

| | | | |
|----------------------------------------|----------------|----------------|-----------------|
| subjects affected / exposed | 3 / 50 (6.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 2 / 49 (4.08%) | 4 / 31 (12.90%) |
| occurrences (all) | 1 | 2 | 4 |
| Gastrooesophageal Reflux Disease | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 49 (2.04%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Noninfective Gingivitis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Post-Tussive Vomiting | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vomiting | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 3 / 49 (6.12%) | 0 / 31 (0.00%) |
| occurrences (all) | 1 | 3 | 0 |
| Hepatobiliary disorders | | | |
| Hepatosplenomegaly | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypertransaminasaemia | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| Asteatosis | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dermatitis Atopic | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 1 / 31 (3.23%) |
| occurrences (all) | 0 | 0 | 1 |
| Dermatitis Diaper | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 49 (2.04%) | 1 / 31 (3.23%) |
| occurrences (all) | 0 | 1 | 1 |
| Eczema | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erythema | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 49 (2.04%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Miliaria | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 49 (2.04%) | 1 / 31 (3.23%) |
| occurrences (all) | 0 | 1 | 1 |
| Rash | | | |
| subjects affected / exposed | 3 / 50 (6.00%) | 1 / 49 (2.04%) | 0 / 31 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Rash Erythematous | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 49 (2.04%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Rash Macular | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rash Papular | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urticaria | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Skin Lesion | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal and urinary disorders | | | |
| Polyuria | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 49 (0.00%) | 1 / 31 (3.23%) |
| occurrences (all) | 1 | 0 | 1 |
| Oliguria | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |

| | | | |
|---------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| Musculoskeletal Stiffness subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 49 (0.00%) 0 | 0 / 31 (0.00%) 0 |
| Infections and infestations | | | |
| Bronchiolitis subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 49 (0.00%) 0 | 0 / 31 (0.00%) 0 |
| Bronchitis subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 49 (0.00%) 0 | 1 / 31 (3.23%) 1 |
| Conjunctivitis subjects affected / exposed occurrences (all) | 2 / 50 (4.00%) 2 | 2 / 49 (4.08%) 2 | 0 / 31 (0.00%) 0 |
| Candida Nappy Rash subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 49 (0.00%) 0 | 0 / 31 (0.00%) 0 |
| Ear Infection subjects affected / exposed occurrences (all) | 1 / 50 (2.00%) 1 | 0 / 49 (0.00%) 0 | 1 / 31 (3.23%) 1 |
| Exanthema Subitum subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 49 (0.00%) 0 | 0 / 31 (0.00%) 0 |
| Fungal Infection subjects affected / exposed occurrences (all) | 1 / 50 (2.00%) 1 | 0 / 49 (0.00%) 0 | 0 / 31 (0.00%) 0 |
| Gastroenteritis subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 2 / 49 (4.08%) 2 | 0 / 31 (0.00%) 0 |
| Hand-Foot-And-Mouth Disease subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 2 / 49 (4.08%) 2 | 0 / 31 (0.00%) 0 |
| Influenza subjects affected / exposed occurrences (all) | 1 / 50 (2.00%) 1 | 0 / 49 (0.00%) 0 | 0 / 31 (0.00%) 0 |
| Localised Infection | | | |

| | | | |
|---------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lower Respiratory Tract Infection Bacterial | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Oral Candidiasis | | | |
| subjects affected / exposed | 2 / 50 (4.00%) | 2 / 49 (4.08%) | 0 / 31 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 2 / 49 (4.08%) | 1 / 31 (3.23%) |
| occurrences (all) | 1 | 2 | 1 |
| Otitis Media | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 49 (0.00%) | 1 / 31 (3.23%) |
| occurrences (all) | 1 | 0 | 1 |
| Parainfluenzae Virus Infection | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Otitis Media Acute | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 2 / 49 (4.08%) | 1 / 31 (3.23%) |
| occurrences (all) | 1 | 2 | 1 |
| Pneumonia | | | |
| subjects affected / exposed | 2 / 50 (4.00%) | 0 / 49 (0.00%) | 1 / 31 (3.23%) |
| occurrences (all) | 2 | 0 | 1 |
| Pneumonia Bacterial | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 49 (2.04%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Respiratory Tract Infection Bacterial | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 1 / 49 (2.04%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Respiratory Tract Infection | | | |
| subjects affected / exposed | 1 / 50 (2.00%) | 1 / 49 (2.04%) | 0 / 31 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Respiratory Tract Infection Viral | | | |
| subjects affected / exposed | 0 / 50 (0.00%) | 0 / 49 (0.00%) | 0 / 31 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| Rhinovirus Infection subjects affected / exposed occurrences (all) | 1 / 50 (2.00%) 1 | 1 / 49 (2.04%) 1 | 0 / 31 (0.00%) 0 |
| Sinusitis subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 1 / 49 (2.04%) 1 | 0 / 31 (0.00%) 0 |
| Tonsillitis subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 49 (0.00%) 0 | 0 / 31 (0.00%) 0 |
| Upper Respiratory Tract Infection subjects affected / exposed occurrences (all) | 4 / 50 (8.00%) 4 | 3 / 49 (6.12%) 3 | 1 / 31 (3.23%) 1 |
| Urinary Tract Infection subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 2 / 49 (4.08%) 2 | 0 / 31 (0.00%) 0 |
| Viral Infection subjects affected / exposed occurrences (all) | 1 / 50 (2.00%) 1 | 0 / 49 (0.00%) 0 | 0 / 31 (0.00%) 0 |
| Viral Rash subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 0 / 49 (0.00%) 0 | 1 / 31 (3.23%) 1 |
| Metabolism and nutrition disorders | | | |
| Hyperuricaemia subjects affected / exposed occurrences (all) | 1 / 50 (2.00%) 1 | 0 / 49 (0.00%) 0 | 0 / 31 (0.00%) 0 |
| Hyperkalaemia subjects affected / exposed occurrences (all) | 1 / 50 (2.00%) 1 | 0 / 49 (0.00%) 0 | 0 / 31 (0.00%) 0 |
| Metabolic Alkalosis subjects affected / exposed occurrences (all) | 1 / 50 (2.00%) 1 | 0 / 49 (0.00%) 0 | 0 / 31 (0.00%) 0 |
| Zinc Deficiency subjects affected / exposed occurrences (all) | 0 / 50 (0.00%) 0 | 1 / 49 (2.04%) 1 | 0 / 31 (0.00%) 0 |

| | | | |
|-----------------------------------|-------------------|---------------------------------|----------------------------------|
| Non-serious adverse events | Cohort 2: Placebo | Cohort 2: JNJ-53718678 Low Dose | Cohort 1: JNJ-53718678 High Dose |
|-----------------------------------|-------------------|---------------------------------|----------------------------------|

| | | | |
|--------------------------------------------------------------------------------------|------------------|------------------|------------------|
| Total subjects affected by non-serious adverse events subjects affected / exposed | 14 / 34 (41.18%) | 20 / 34 (58.82%) | 30 / 48 (62.50%) |
| Vascular disorders | | | |
| Haematoma | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperaemia | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all) | 0 | 0 | 1 |
| General disorders and administration site conditions | | | |
| Face Oedema | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperthermia | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oedema Peripheral | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 34 (2.94%) | 3 / 48 (6.25%) |
| occurrences (all) | 0 | 1 | 3 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Asthma | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Atelectasis | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all) | 0 | 0 | 1 |
| Bronchial Obstruction | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all) | 0 | 0 | 1 |
| Bronchial Secretion Retention | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bronchospasm | | | |

| | | | |
|------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all) | 0 | 0 | 1 |
| Catarrh | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cough | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysphonia | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lung Consolidation | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all) | 0 | 0 | 1 |
| Epistaxis | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 34 (2.94%) | 1 / 48 (2.08%) |
| occurrences (all) | 0 | 1 | 1 |
| Dyspnoea | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 34 (2.94%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nasal Discomfort | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory Depth Increased | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory Distress | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinorrhoea | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 1 / 34 (2.94%) | 0 / 48 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Sinus Disorder | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all) | 0 | 0 | 1 |
| Upper Respiratory Tract Congestion | | | |

| | | | |
|------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper Respiratory Tract Inflammation | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all) | 0 | 0 | 1 |
| Wheezing | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Psychiatric disorders | | | |
| Restlessness | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all) | 0 | 0 | 1 |
| Investigations | | | |
| Alanine Aminotransferase Increased | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 34 (2.94%) | 1 / 48 (2.08%) |
| occurrences (all) | 0 | 1 | 1 |
| Aspartate Aminotransferase Increased | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all) | 0 | 0 | 1 |
| Blood Creatinine Increased | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 34 (2.94%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Blood Potassium Increased | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oxygen Saturation Decreased | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Platelet Count Increased | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Transaminases Increased | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Injury, poisoning and procedural complications | | | |

| | | | |
|--------------------------------------|----------------|----------------|----------------|
| Arthropod Sting | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 34 (2.94%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Contusion | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Head Injury | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all) | 0 | 0 | 1 |
| Skin Wound | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Radial Head Dislocation | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all) | 0 | 0 | 1 |
| Eosinophilia | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all) | 0 | 0 | 1 |
| Leukopenia | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lymphocytosis | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 34 (2.94%) | 1 / 48 (2.08%) |
| occurrences (all) | 0 | 1 | 1 |
| Lymphadenopathy | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutropenia | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 2 / 48 (4.17%) |
| occurrences (all) | 0 | 0 | 2 |
| Thrombocytosis | | | |

| | | | |
|--------------------------------------------------|---------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 34 (0.00%) 0 | 2 / 34 (5.88%) 2 | 3 / 48 (6.25%) 3 |
| Eye disorders | | | |
| Eye Discharge | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ocular Hyperaemia | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Gastrointestinal disorders | | | |
| Anorectal Discomfort | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all) | 0 | 0 | 1 |
| Anal Erythema | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Constipation | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Faeces Soft | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 2 / 48 (4.17%) |
| occurrences (all) | 0 | 0 | 3 |
| Diarrhoea | | | |
| subjects affected / exposed | 5 / 34 (14.71%) | 3 / 34 (8.82%) | 5 / 48 (10.42%) |
| occurrences (all) | 5 | 3 | 5 |
| Gastrooesophageal Reflux Disease | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Noninfective Gingivitis | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all) | 0 | 0 | 1 |
| Post-Tussive Vomiting | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all) | 0 | 0 | 1 |
| Vomiting | | | |

| | | | |
|--------------------------------------------------|----------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 4 / 34 (11.76%) 4 | 1 / 34 (2.94%) 1 | 3 / 48 (6.25%) 3 |
| Hepatobiliary disorders | | | |
| Hepatosplenomegaly | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 34 (2.94%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hypertransaminasaemia | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| Asteatosis | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 34 (2.94%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Dermatitis Atopic | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all) | 0 | 0 | 1 |
| Dermatitis Diaper | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 34 (2.94%) | 3 / 48 (6.25%) |
| occurrences (all) | 0 | 1 | 3 |
| Eczema | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 1 / 34 (2.94%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Erythema | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all) | 0 | 0 | 1 |
| Miliaria | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 2 / 34 (5.88%) | 3 / 48 (6.25%) |
| occurrences (all) | 0 | 2 | 3 |
| Rash Erythematous | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash Macular | | | |

| | | | |
|----------------------------------------------------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 34 (0.00%) 0 | 0 / 34 (0.00%) 0 | 0 / 48 (0.00%) 0 |
| Rash Papular subjects affected / exposed occurrences (all) | 0 / 34 (0.00%) 0 | 1 / 34 (2.94%) 1 | 1 / 48 (2.08%) 1 |
| Urticaria subjects affected / exposed occurrences (all) | 0 / 34 (0.00%) 0 | 0 / 34 (0.00%) 0 | 1 / 48 (2.08%) 1 |
| Skin Lesion subjects affected / exposed occurrences (all) | 0 / 34 (0.00%) 0 | 0 / 34 (0.00%) 0 | 1 / 48 (2.08%) 1 |
| Renal and urinary disorders Polyuria subjects affected / exposed occurrences (all) | 0 / 34 (0.00%) 0 | 0 / 34 (0.00%) 0 | 0 / 48 (0.00%) 0 |
| Oliguria subjects affected / exposed occurrences (all) | 0 / 34 (0.00%) 0 | 0 / 34 (0.00%) 0 | 0 / 48 (0.00%) 0 |
| Musculoskeletal and connective tissue disorders Musculoskeletal Stiffness subjects affected / exposed occurrences (all) | 0 / 34 (0.00%) 0 | 0 / 34 (0.00%) 0 | 1 / 48 (2.08%) 1 |
| Infections and infestations Bronchiolitis subjects affected / exposed occurrences (all) | 0 / 34 (0.00%) 0 | 0 / 34 (0.00%) 0 | 1 / 48 (2.08%) 1 |
| Bronchitis subjects affected / exposed occurrences (all) | 0 / 34 (0.00%) 0 | 1 / 34 (2.94%) 1 | 0 / 48 (0.00%) 0 |
| Conjunctivitis subjects affected / exposed occurrences (all) | 0 / 34 (0.00%) 0 | 0 / 34 (0.00%) 0 | 0 / 48 (0.00%) 0 |
| Candida Nappy Rash subjects affected / exposed occurrences (all) | 0 / 34 (0.00%) 0 | 0 / 34 (0.00%) 0 | 1 / 48 (2.08%) 1 |
| Ear Infection | | | |

| | | | |
|------------------------------------------------|----------------|----------------|-----------------|
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Exanthema Subitum | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Fungal Infection | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 2 / 48 (4.17%) |
| occurrences (all) | 0 | 0 | 2 |
| Hand-Foot-And-Mouth Disease | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 2 / 34 (5.88%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Localised Infection | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all) | 0 | 0 | 1 |
| Lower Respiratory Tract Infection Bacterial | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral Candidiasis | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 2 / 34 (5.88%) | 6 / 48 (12.50%) |
| occurrences (all) | 0 | 2 | 6 |
| Otitis Media | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 34 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all) | 1 | 0 | 1 |
| Parainfluenzae Virus Infection | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---------------------------------------|----------------|----------------|----------------|
| Otitis Media Acute | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 34 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all) | 1 | 0 | 1 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all) | 0 | 0 | 1 |
| Pneumonia Bacterial | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all) | 0 | 0 | 1 |
| Respiratory Tract Infection Bacterial | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory Tract Infection | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all) | 0 | 0 | 1 |
| Respiratory Tract Infection Viral | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rhinovirus Infection | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tonsillitis | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 1 / 34 (2.94%) | 0 / 48 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Upper Respiratory Tract Infection | | | |
| subjects affected / exposed | 1 / 34 (2.94%) | 0 / 34 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all) | 1 | 0 | 1 |
| Urinary Tract Infection | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all) | 0 | 0 | 1 |
| Viral Infection | | | |
| subjects affected / exposed | 0 / 34 (0.00%) | 0 / 34 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| Viral Rash subjects affected / exposed occurrences (all) | 0 / 34 (0.00%) 0 | 0 / 34 (0.00%) 0 | 1 / 48 (2.08%) 1 |
| Metabolism and nutrition disorders | | | |
| Hyperuricaemia subjects affected / exposed occurrences (all) | 0 / 34 (0.00%) 0 | 0 / 34 (0.00%) 0 | 0 / 48 (0.00%) 0 |
| Hyperkalaemia subjects affected / exposed occurrences (all) | 0 / 34 (0.00%) 0 | 0 / 34 (0.00%) 0 | 0 / 48 (0.00%) 0 |
| Metabolic Alkalosis subjects affected / exposed occurrences (all) | 0 / 34 (0.00%) 0 | 0 / 34 (0.00%) 0 | 0 / 48 (0.00%) 0 |
| Zinc Deficiency subjects affected / exposed occurrences (all) | 0 / 34 (0.00%) 0 | 0 / 34 (0.00%) 0 | 0 / 48 (0.00%) 0 |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 14 May 2019 | The purpose of this amendment was to increase the sample size of Cohort 1 (hospitalized cohort) from 24 to 48 subjects per treatment arm to increase the precision on the estimates for the clinical course related endpoints in this cohort. |
| 05 July 2019 | The purpose of this amendment was to clarify how the required balance within the symptom onset randomization strata (symptom onset less than or equal to (\leq) 3 days and greater than ($>$) 3 days to \leq 5 days) for each of the interim analyses as well as for the final analysis will be achieved while allowing some flexibility in view of respiratory syncytial virus (RSV) seasonality and reducing the recruitment impact of a (temporary) pause in enrollment in one of the strata. |
| 20 December 2019 | The purpose of this amendment was to allow unblinding of the central sponsor team and selected local sponsor representatives from Japan to the data included in the second interim analysis and to allow unblinding of the sponsor, including the study team, and selected local sponsor representatives from Japan to all interim analyses planned after the second interim analysis. |
| 26 May 2020 | The purpose of this amendment was to implement a risk mitigation plan following identification of an exposure (C_{max})-related important potential risk of QT interval prolongation identified in the throughout QT (TQT) Study 53718678RSV1009 in healthy adult subjects. Given that Cohort 1 enrollment has completed and no more Cohort 1 subjects were ongoing in the study. |
| 10 July 2020 | The purpose of this amendment was to implement recommendations from Health Authorities (HA). Given that Cohort 1 enrollment had completed and no more Cohort 1 subjects were ongoing in the study, the changes were only applicable for the newly to be recruited Cohort 2 subjects. |
| 01 December 2020 | The purpose of this amendment was to maximize enrollment of subjects with at least moderate RSV disease severity, where potentially greater treatment benefit was achieved. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported